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Individuals with serious mental illness (SMI) are disproportionately impacted by 
preventable physical health conditions, which put them at risk for premature mortality. Integrated 
primary and behavioral health care (PBHC) programs have demonstrated promise in treating 
comorbid physical and mental health conditions, common to individuals diagnosed with SMI. 
The current study focused on individuals with thought disorders (i.e., schizophrenia, 
schizoaffective disorder, and brief psychotic disorder), as those diagnosed are more likely to be 
retained in care. Treatment retention is especially important, as adherence slows down the 
progression of psychiatric symptoms and physical health diseases. Extant research has focused 
on evaluation of the efficacy of PBHC programs. This exploratory secondary analysis 
contributes to the growing knowledge base of research on integrated PBHC programs and the 
clients who receive these services by examining relevant correlates (i.e., sociodemographic, 
health, health-risk, and treatment-related characteristics) of health and psychosocial 
improvements among 311 individuals with thought disorders receiving co-located services in 3 
community mental health (CMH) settings. Variables significantly associated with improvements 
in health and psychosocial characteristics included employment status, disability status, living 
situation, access to reliable transportation, and clinic site, suggesting that social determinants are 
relevant for this population. Directions for future research and implications for social work 






CHAPTER 1: INTRODUCTION 
Serious mental illness (SMI) is a major social welfare issue of concern for social workers 
employed in diverse health and mental health settings. The current study examined correlates of 
health and psychosocial improvements among individuals with thought disorders (i.e., 
schizophrenia, schizoaffective disorder, brief psychotic disorder) receiving integrated primary 
and behavioral health care (PBHC) services in community mental health (CMH) settings. This 
chapter provides an overview of the pervasiveness of SMI and the health disparities that this 
population faces, with a special focus on thought disorders. Additionally, the biopsychosocial 
(BPS) model is introduced as a relevant theoretical framework for conceptualizing the topic of 
study. Finally, the study’s significance to the field of social work is discussed. 
Problem Statement  
It is well known that individuals with SMI are disproportionately affected by physical 
health conditions, which often lead to the development of serious comorbidities and premature 
mortality (Parks, Svendsen, Singer, & Foti, 2006). Efforts have been made to eliminate existing 
health disparities through federally-supported grants (Scharf et al., 2013), and evaluative studies 
(Druss et al., 2010; Putz et al., 2015) have demonstrated the effectiveness of government-funded 
PBHC programs in CMH settings. However, prior to this analysis, no study to date had examined 
potential correlates (i.e., sociodemographic, health, health-risk, and treatment-related 
characteristics) of health and psychosocial improvements among individuals with thought 
disorders receiving integrated services in CMH settings. New knowledge about potential 
predictors of improvement may help guide social workers in direct practice and policy-practice 
roles with regard to developing resources and systematic efforts to strengthen services to this 
vulnerable subpopulation of clients with SMI. 
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Importance of the Problem 
 SMI can be very debilitating for affected individuals, as those diagnosed experience a 
variety of complex psychiatric symptoms (American Psychiatric Association [APA], 2013), 
stigma (Stuart & Arboleda-Flórez, 2012), and high rates of comorbid physical health conditions 
(Parks et al., 2006). This crisis extends beyond the individual level, impacting family members 
of those affected and the public at large (Kennedy, 2013). Loved ones of persons with SMI often 
face some level of stigma (Sartorius, 2002) and are often left with the hefty financial costs of 
treatment (Kennedy, 2013). Further, in terms of public health resources, communities are 
impacted by the frequent emergency room visits, hospitalizations, and incarcerations of 
individuals with SMI (Kennedy, 2013).   
Scope of the Problem 
 SMI, defined by the Substance Abuse and Mental Health Services Administration 
(SAMHSA, 2016) as any mental or behavioral disorder that causes significant impairment in an 
individual’s day-to-day living, includes both mood disorders (e.g., major depression, bipolar 
disorder) and thought disorders. Approximately 4% of adults in the United States (an estimated 
9.8 million) have SMI (SAMHSA, 2016).  
 The extent research shows that persons diagnosed with SMI live, on average, 25 years 
less than the general population (Parks et al., 2006). According to Parks et al. (2006), 60% of 
premature deaths among those specifically diagnosed with thought disorders can be attributed to 
preventable physical health conditions (e.g., cardiovascular disease, pulmonary disease, 
infectious disease). Further, most of the risk factors that contribute to these diseases (e.g., 
smoking, alcohol consumption, drug use, poor nutrition, sedentary lifestyle) are modifiable 
(Parks et al., 2006).  
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 Despite the high prevalence rates of physical health conditions among individuals with 
SMI, evidence from a variety of sources shows that they are less likely to visit physicians for 
routine medical care than the general population (Druss & Walker, 2011). Further, studies 
conducted in the last decade or so show that those who do have some source of routine medical 
care often receive subpar services (Miller, Druss, Dombrowski, & Rosenheck, 2003). As 
individuals with SMI are more likely to seek health care services through CMH centers, these 
agencies are the ideal locations to provide coordinated, integrated PBHC services (Druss et al., 
2010). The shift toward integrated care is relatively new (Scharf et al., 2013), so little research 
evaluating program effectiveness has been published. However, two studies (Druss et al., 2010; 
Putz et al., 2015) examining the effectiveness of integrated programs in CMH settings have 
demonstrated promising results with regard to improved health outcomes. The next step for 
researchers is to examine relevant correlates of health and psychosocial improvements, and this 
study precisely sought to identify empirically relevant predictors of improvement among clients 
with thought disorders receiving integrated PBHC services.  
 This exploratory secondary analysis used existing data collected at baseline and follow up 
from clients with thought disorders enrolled in integrated PBHC programs at three CMH centers. 
The current study sought to determine which sociodemographic, health, health-risk, and 
treatment-related characteristics were associated with health and psychosocial improvements.  
Theoretical Significance 
 The current study is rooted in BPS theory. George L. Engel, a psychiatrist, first 
introduced the BPS model in 1977. This theory claims that an individual’s wellbeing is impacted 
by biological, psychological, and social factors (Engel, 1977); further, BPS theory asserts that a 
holistic approach addressing all three of the aforementioned dimensions is necessary when 
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treating individuals (Engel, 1977). As people with SMI experience numerous psychiatric 
symptoms and comorbid physical health conditions, which are often created or exacerbated by 
environmental factors (Druss & Walker, 2011), an understanding of the multiple factors and their 
interrelationships is critical for conceptualizing this descriptive study.  
Contributions to the Field of Social Work 
 According to the National Association of Social Workers’ (NASW, 2017) Code of 
Ethics, social workers have an ethical responsibility to “pursue social change, particularly with 
and on behalf of vulnerable and oppressed individuals and groups of people.” Individuals with 
SMI are still among the most stigmatized groups in society (Stuart & Arboleda-Flórez, 2012), 
and in addition to suffering from a variety of complex psychiatric symptoms (APA, 2013), 
people with SMI are disproportionately affected by comorbid physical health conditions (Parks 
et al., 2006). Individuals with SMI are at increased risk for experiencing stigma, chronic 
diseases, and premature mortality (Parks et al., 2006); thus, social workers must focus their 
efforts towards eliminating these disparities. 
 According to NASW (n.d.), social workers account for 60% of the mental health 
workforce. As such, they are in the ideal position to advocate for individuals with SMI. As 
systems of care move toward greater integration (Gerrity, Zoller, Pinson, Pettinari, & King, 
2014), understanding the characteristics associated with improvements in health and 
psychosocial outcomes among CMH clients with SMI enrolled in integrated PBHC programs is 
timely. The current study focused specifically on clients with thought disorders, as they are less 
understood and more likely to receive social rejection and less compassion (Angermeyer & 
Deitrich, 2006). In addition, recent investigations show that CMH clients with thought disorders 
are more likely than those with mood disorders to be retained in care (Thomas, 2017; Lemieux, 
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Thomas, Newransky, Khalifa, & Hebert, 2017). This is important because treatment retention is 
associated with improved health and psychosocial outcomes for this particular population (Druss 
& Walker, 2011; Adair et al., 2005). Results generated from this study may help social work and 
other health practitioners identify potential predictors (i.e., sociodemographic, health, health-risk, 
and treatment-related characteristics) that indicate areas of risk and resilience regarding health 
and psychosocial improvements among individuals with thought disorders. Such knowledge may 
guide social workers engaged in direct practice and policy-practice roles to develop and test 
relevant interventions, including recovery support services that target health- and psychosocial-
















CHAPTER 2: REVIEW OF THE LITERATURE 
This chapter reviews existing literature on the pervasiveness of SMI and the increased 
physical health risks among this population. The analysis has a special focus on thought 
disorders; thus, discussion focuses on diagnostic criteria, prevalence rates, best practices, risks 
for deterioration, information on mental health stigma, and statistics on physical and mental 
health comorbidity. Models of integrated PBHC have demonstrated promise in treating comorbid 
mental and physical health conditions, and a summary of major evaluation findings and 
implications will be provided. Finally, treatment retention and disengagement will be reviewed. 
An Overview of Serious Mental Illnesses and Thought Disorders 
According to SAMHSA (2016), SMI can be defined as any mental or behavioral disorder 
that causes significant impairment in one’s functioning and one’s ability to complete major 
activities. Approximately 4% of adults in the United States (an estimated 9.8 million) have SMI 
(SAMHSA, 2016). Of the portion of adults with SMI, roughly 5% are female and about 3.1% are 
male (SAMHSA, 2015). Whites have higher prevalence rates (4.4%) than Hispanic/Latinos 
(3.5%), Blacks (3.1%), and Asians (2.4%; SAMHSA, 2015). Individuals without health 
insurance are more likely to be diagnosed with SMI than individuals with health coverage 
(SAMHSA, 2015). Additionally, individuals who live below the federal poverty level are almost 
2 times more likely to have SMI than those who live above the federal poverty level (SAMHSA, 
2015).  
 SMI includes both mood disorders (e.g., major depression, bipolar disorder) and thought 
disorders (i.e., schizophrenia, schizoaffective disorder, brief psychotic disorder). This analysis 
will focus on different aspects of thought disorders.  
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Schizophrenia   
 Prevalence and Incidence. According to the World Health Organization (WHO, 2016), 
approximately 21 million people are affected by schizophrenia worldwide. The American 
Psychiatric Association (APA, 2013) stated that prevalence rates range from 0.3% to 0.7%, with 
some variation across countries. The median incidence of schizophrenia is roughly 0.20 per 
1,000 persons annually (Messias, Chen, & Eaton, 2007). 
Symptoms and Primary Diagnostic Criteria. In order for a diagnosis of schizophrenia 
to be established, there must be an active phase, that is, a period in which at least two of the 
following symptom categories are present: delusions, hallucinations, disorganized speech, 
behavioral disturbances of either disorganization or catatonia, and negative symptoms (APA, 
2013). Furthermore, at least one of the two required symptom categories are delusions, 
hallucinations, or disorganized speech. Negative symptoms include diminished emotional 
expression, avolition (i.e., decreased motivation and interests), alogia (i.e., poverty of speech), 
anhedonia, and asociality (APA, 2013).  
 Additional criteria must be met for a diagnosis of schizophrenia. Symptoms must last at 
least 6 months, a portion of which must include an active phase of at least 1 month’s duration, 
but it can be shorter if treatment reduces the length of the symptomatic period (APA, 2013). 
Active-phase symptoms must not appear solely in the context of a mood episode. Symptoms of 
the prodromal-phase (i.e., a period preceding or leading up to an active phase) or the residual-
phase (i.e., a period following an active phase) must include negative symptoms or reduced 
forms of active-phase symptoms. Symptoms cannot be the result of a substance or some other 
health condition. Finally, the disorder must interfere with functioning in work, relationships, or 
activities of daily living (APA, 2013). 
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Gender and Race Considerations. Men are more likely than women to receive a 
diagnosis of schizophrenia (WHO, 2016), and men with the disorder usually experience their 
first psychotic episode at an earlier age than women with the disorder (Andreasen & Black, 
2006). Overall, women tend to experience less severe functional deficits prior to the onset of the 
illness, as well as experience fewer symptoms as the disorder progresses (Canuso & Pandina, 
2007).  
Although White individuals have a higher prevalence of SMI than other races, Black 
individuals are disproportionately diagnosed with schizophrenia, with race emerging as the most 
influential factor when diagnosing schizophrenia in a hospital setting (Barnes, 2013). After 
controlling for age, gender, education, and number of prior hospitalizations, Barnes (2013) found 
that Black clients were twice as likely as White clients to be diagnosed with schizophrenia. 
Another earlier study by Barnes (2008) showed that White clients were more likely than Black 
clients to be diagnosed with a mood disorder than with schizophrenia. As noted by Barnes 
(2008), misdiagnosis of schizophrenia can lead to individuals being prescribed medications that 
are inappropriate for their actual diagnoses, which can expose them to unnecessary side effects 
and other health problems.  
 Racial disparities also emerge in the pharmacological treatment of schizophrenia. For 
example, Kreyenbuhl, Zito, Buchanan, Soeken, and Lehman (2003) analyzed data collected with 
the Schizophrenia Patient Outcome Research Team (PORT) and showed that Black persons with 
schizophrenia were 3 times more likely than White persons with schizophrenia to receive long-
acting injectable antipsychotics. Results also showed that Black individuals were 76% less likely 
than White individuals to receive the newer atypical antipsychotic medications, even after 
	 9	
controlling for age, gender, education, and number of prior hospitalizations (Kreyenbuhl et al., 
2003).   
Best Practices and Treatment Considerations. According to Chien and Yip (2013), the 
use of antipsychotic medication continues to be the primary form of treatment for individuals 
with schizophrenia. Additionally, recent meta-analyses suggest that psychosocial interventions in 
combination with medications are effective in reducing acute psychotic symptoms, slowing 
illness progression, and maintaining remission (Chien & Yip, 2013).  
Keating et al. (2017) completed a systematic review of existing clinical practice 
guidelines on treating positive symptoms in first-episode schizophrenia. A total of 3,299 articles 
containing treatment recommendations were retrieved from PubMed and EMBASE databases 
(Keating et al., 2017). After comparing clinical practice guideline content from included studies, 
Keating et al. (2017) compiled a list of recommendations. Overwhelmingly, clinical practice 
guidelines concurred/showed that typical and atypical antipsychotics were equally effective in 
treating first-episode psychotic symptoms (Keating et al., 2017). Results also indicated that the 
benefits of an antipsychotic medication regimen are generally evident within the first 2 weeks; 
however, 4 weeks is the generally recommended duration for determining the benefit of a 
particular antipsychotic regimen (Keating et al., 2017).  
Recently, there has been much debate over the potential superiority of second-generation 
(atypical) antipsychotics over first-generation antipsychotics. Tandon et al. (2008) examined the 
effectiveness of 62 antipsychotic (51 first-generation and 11 second-generation) medications 
using data from about 1,600 clinical trials and concluded that second-generation antipsychotics 
were as effective as first-generation antipsychotics with regard to treating positive symptoms 
(Tandon et al., 2008). However, the superior benefits of second-generation medications for 
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negative symptoms, cognition, and depression were not consistently demonstrated (Tandon et al., 
2008). The atypical antipsychotic clozapine was superior to the first-generation antipsychotics 
and the other second-generation antipsychotics, and also had the most benefit for treatment-
resistant psychosis (Tandon et al., 2008). Nevertheless, due to the risk of neutropenia (i.e., 
excessively low numbers of white blood cells) clozapine is reserved for people who have failed 
two or more trials of antipsychotic medications (Tandon et al., 2008).  
Keating et al. (2017) concluded that consideration of medication side effects is the most 
important factor in selecting an antipsychotic medication. Atypical agents, compared to 
neuroleptic medications, have a lower risk of extrapyramidal side effects (i.e., muscle tightening 
or movement problems) and tardive dyskinesia (Tandon et al., 2008). However, second-
generation medications generally pose greater risks for the metabolic effects of weight gain, 
diabetes, and dyslipidemia, all of which are risk factors for heart disease and increased mortality 
(Tandon et al., 2008). Metabolic side effects vary by agent among the atypical antipsychotics, 
with clozapine and olanzapine resulting in the greatest degree and ziprasidone causing the least 
(Tandon et al., 2008). The balanced risk of adverse side effects should be considered when 
selecting the best psychotropic medication for a particular individual.  
The Schizophrenia PORT also generated several treatment recommendations based on 
systematic reviews of existing literature (Kreyenbuhl, Buchanan, Dickerson, & Dixon, 2010). 
Pharmacological treatment recommendations paralleled those suggested by Tandon et al. (2008), 
but Kreyenbuhl et al. (2010) extended their systematic analysis further by investigating existing 
psychosocial treatment recommendations. Medications fail to adequately treat negative 
symptoms; thus, psychosocial treatments are critical for enhancing quality of life and medication 
adherence (Elis, Caponigro, & Kring, 2013). For example, cognitive behavioral therapy was 
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effective in reducing symptom severity, and family-based services of at least 6 to 9 months in 
duration helped to significantly decrease rates of relapse (Kreyenbuhl et al., 2010). A key factor 
in family therapy is addressing the issue of expressed emotion, “an empirically derived index of 
criticism, overinvolvement, and hostility” (p. 164), by family members of individuals with 
schizophrenia (Bustillo, Laurielle, Horan, & Keith, 2001). Research has shown that changes in 
expressed emotion (from higher to lower levels) are associated with decreased rates of relapse 
(Bustillo et al., 2001).  
 Risk Factors for Deterioration/Hospitalizations. According to Keating et al. (2017), 
relapse (i.e., a worsening of symptoms after a period of improvement or return of symptoms 
following remission) occurs in about 3 out of 4 people with schizophrenia. Weiden, Kozma, 
Grogg, and Locklear (2004) examined 4,325 Medicaid pharmacy refill and claims forms of 
individuals with schizophrenia to determine the relationship between adherence to antipsychotics 
and hospitalization. Results indicated that even small gaps in medication adherence (i.e., 1 to 10 
days) significantly increased the likelihood of hospitalization (Weiden et al., 2004). Results also 
showed that hospitalization occurred more frequently among Black individuals and among 
Medicare-eligible individuals (Weiden et al., 2004). Other studies suggest that relapse is strongly 
associated with lower premorbid functioning (Üçok, Polat, Çakır, & Genç, 2006), co-occurring 
substance use disorders (SUD; Malla et al., 2008), and lack of insight (Drake et al., 2007). 
Further, as previously noted, higher levels of expressed emotion within families are associated 
with increased rates of relapse (Bustillo et al., 2001).  
 Approximately 11% of the homeless population has schizophrenia, and this type of living 
arrangement is associated with worse outcomes (Foster, Gable, & Buckley, 2012). Many 
individuals with schizophrenia who are homeless receive subpar service planning, as well as 
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discontinue using available treatment (Foster et al., 2012). Individuals with SMI who are 
homeless may discontinue their medication regimens because they are not closely monitored in 
the community; as a result, many deteriorate quickly and are hospitalized (Lamb & Bachrach, 
2001). 
Schizoaffective Disorder 
Prevalence and Incidence. According to the APA (2013), schizoaffective disorder is not 
as common as schizophrenia and has a lifetime prevalence rate of 0.3%. Incidence rates are 
unclear due to recent changes in diagnostic criteria (Brannon, 2012). Prior to the DSM-5, the 
diagnosis was used more frequently than intended. Current criteria emphasize the lifetime course 
of the illness, as opposed to consideration of potentially isolated episodes described in previous 
manuals (Malaspina et al., 2013). The change is intended to ensure that criteria are consistently 
applied, which ultimately will lead to reduced rates of schizoaffective diagnoses (Malaspina et 
al., 2013). 
 Symptoms and Primary Diagnostic Criteria. In order to establish a diagnosis of 
schizoaffective disorder, an episode of a mood disorder must occur along with an active phase of 
schizophrenia (APA, 2013). In addition, there must also be a period of at least 2 weeks of 
hallucinations or delusions without a mood episode (in order to rule out a psychotic mood 
disorder), mood episodes must occur over most of the active and residual phases of the disorder, 
and symptoms cannot be the result of a substance or some other health condition (APA, 2013). 
Gender and Race Considerations. Women are more likely than men to receive a 
diagnosis of schizoaffective disorder (APA, 2013), and a study by Robinson et al. (1999) found 
that female participants with first-episode schizoaffective disorder responded better to 
antipsychotics than did male participants. Although Black individuals are more likely to receive 
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a diagnosis of schizophrenia than White individuals, racial differences are not apparent among 
individuals diagnosed with schizoaffective disorder (Neighbors, Trierweiler, Ford, & Muroff, 
2003). 
 Best Practices and Treatment Characteristics. According to Levinson, Umapathy, and 
Musthaq (1999), the majority of individuals diagnosed with schizoaffective disorder are treated 
with antipsychotics, thymoleptics (i.e., drugs that modify mood), antidepressants, or a 
combination of medications. Levinson et al. (1999) examined 18 treatment studies of 
schizoaffective disorder and found that antipsychotics alone were just as effective as 
combinations when treating acute symptoms; however, once psychotic symptoms were in 
remission, a combination of both antidepressants and antipsychotics helped alleviate symptoms 
of major depression (Levinson et al., 1999). On the other hand, lithium (a thymoleptic) was not 
effective in treating depressive symptoms or mania (Levinson et al., 1999). 
 Risk Factors for Deterioration/Hospitalizations. As with schizophrenia, the risk of 
relapse is common among individuals with schizoaffective disorder (Gaebel et al., 2010). 
Robinson et al. (1999) sought to determine the characteristics associated with relapse among 
individuals with first-episode schizophrenia (N=71) and schizoaffective disorder (N=33) who 
had achieved remission following initial episodes and found that nonadherence to antipsychotic 
medication made relapse 5 times more likely. In addition, Robinson et al. (1999) demonstrated 
that poor premorbid functioning and social withdrawal correlated with earlier relapse and that 
despite careful monitoring, second and third relapses were common among individuals who had 
recovered from first relapses. Murru et al. (2012) completed a longitudinal study with 76 
individuals diagnosed with schizoaffective disorder and found that individuals who did not 
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adhere to treatment recommendations (N=32) primarily experienced psychotic (non-affective) 
symptom episodes.  
Brief Psychotic Disorder 
 Prevalence and Incidence. According to the APA (2013), approximately 9% of all first-
onset psychotic disturbances in the United States meet criteria for brief psychotic disorder. 
Castagnini, Bertelsen, and Berrios (2008) found that the median incidence of brief psychotic 
disorder is roughly 9.6 per 100,000 persons annually. Women are twice as likely as men to 
receive a diagnosis of brief psychotic disorder, and the condition occurs more frequently in 
developing countries (APA, 2013). 
 Symptoms and Primary Diagnostic Criteria. In order to establish a diagnosis of brief 
psychotic disorder, delusions, hallucinations, or disorganized speech must occur for at least 1 
day, but for no more than 1 month (APA, 2013). The episode may also include disorganized 
behavior or catatonia. The psychosis may occur with or without a stressor, and it may appear in a 
peripartum period (APA, 2013). In addition, any psychosis associated with a mood episode, the 
influence of a substance, and the effect of a medical condition must be ruled out (APA, 2013). 
Best Practices and Treatment Considerations. With brief psychotic disorder, the goal 
of treatment is to help individuals return to their previous level of functioning (APA, 2013). 
According to Memon (2015a), symptoms of brief psychotic disorder should be treated with 
antipsychotic medications, and because psychotic episodes are time limited, medication regimens 
should not extend beyond 1 month. Currently, there is no evidence supporting the superiority of 
atypical agents over neuroletpics in treating the disorder (Memon, 2015a). Intramuscular 
ziprasidone (Brook, Lucey, & Gunn, 2000) and rapid tranquilization with olanzapine (Karagianis 
et al., 2001) have been demonstrated to be effective in treating acute psychotic aggression. 
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Individuals with brief psychotic disorder are at greater risk of harming themselves and others 
during acute episodes (Jorgensen & Mortensen, 1990). Thus, Memon (2015a) recommends 
hospitalization if safety is a concern. 
Risk Factors for Deterioration/Hospitalizations. Typically, brief psychotic disorder 
has a good prognosis, and 50-80% of those diagnosed experience no major subsequent 
psychiatric issues (Memon, 2015b). Correll et al. (2008) observed that individuals with brief 
psychotic disorder who also demonstrate executive functional deficits may go on to develop 
schizophrenia; whereas those with co-occurring brief psychotic disorder and anxiety symptoms 
may eventually develop bipolar disorder (Correll et al., 2008). 
Stigma and Its Consequences 
According to Stuart and Arboleda-Flórez (2012), “Mental illness stigma occurs when 
individuals are devalued or treated unfairly by others because of their mental health condition” 
(p. 1). Despite increased public awareness of mental illnesses, people with mental disorders are 
still among the most stigmatized groups in society (Stuart & Arboleda-Flórez, 2012), and this 
burden extends to family members, as well as to mental health providers, whose careers are not 
acknowledged and valued as much as those of professionals in other health disciplines (Sartorius, 
2002).  
 Data collected from the general public and from those with mental disorders indicate 
widespread prevalence of mental illness stigma. For example, Angermeyer and Deitrich (2006) 
reviewed national (N=33) and local (N=29) surveys of public attitudes to determine the 
magnitude of mental health stigma and found that individuals with schizophrenia or SUD 
received less sympathy and more social rejection than individuals with depression. Pescosolido, 
Monahan, Link, Stueve, and Kikuzawa (1999) extracted a random sample of interviews 
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(N=1,444) from the 1996 General Social Survey, which prompted respondents to evaluate the 
competence of individuals in a variety of case vignettes. The majority of respondents believed 
that individuals with schizophrenia were incapable of making treatment decisions (75.3%), 
unable to manage money (70.2%), and likely to commit violent acts against others (60.9%). The 
belief that persons with mental illness are violent is one of many prejudices held by the public at 
large, and these attitudes engender discriminatory actions against individuals with mental 
disorders (Arboleda-Flórez & Sartorius, 2008). 
 Wahl (1999) conducted a large-scale survey of people with mental illness in order to 
examine the impact of stigma on their lives. Of the 1,388 individuals who completed the survey, 
74% indicated that they avoided disclosing their mental health diagnoses to non-family 
members, 71% denied having a mental illness on applications to evade discrimination, 31% 
reported having been turned down for a job due to their mental illness, and 10% reported 
hesitancy to seek treatment due to fear of judgment (Wahl, 1999). Thornicroft et al. (2009) 
surveyed 732 individuals with schizophrenia across 27 countries and found that almost half 
(47%) of the respondents reported experiencing some type of discrimination (e.g., inability to 
make or keep friends, judgment by family members, trouble finding and keeping work, difficulty 
finding a romantic partner). Most notably, almost three fourths (72%) of respondents reported 
concealing their diagnoses to avoid anticipated discrimination (Thornicroft et al., 2009). A study 
by Brohan, Elgie, Sartorius, Thornicroft, and GAMIAN-Europe Study Group (2010) analyzed 
1,229 surveys from individuals diagnosed with schizophrenia or other psychotic disorders and 
found that 69% believed that the general population thought negatively about them, 48% 
experienced discrimination, 47% suffered alienation, and 45% resorted to social withdrawal. 
Stuart and Arboleda-Flórez (2012) underscored the negative impact of stigma on recovery and 
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recommended that mental health professionals promote client empowerment, identify prevention 
strategies, and educate the public about common misconceptions.  
 A substantial portion of the general public erroneously believes that individuals with 
schizophrenia and other thought disorders are inherently violent, and Lamb and Bachrach (2001) 
suggest that some of these misconceptions might stem from the collateral effects of 
deinstitutionalization. In 1955, approximately 559,000 individuals with SMI occupied state 
mental hospital beds, a number that drastically decreased to only 57,151 in 1998 (Lamb & 
Bachrach, 2001). During this period, proponents of deinstitutionalization believed that 
community-based care would be more humane, beneficial, and cost-effective than state hospital 
care (see, e.g., Bachrach, 1976; Bachrach, 1978; Thornicroft & Bebbington, 1989). However, 
many deinstitutionalized individuals with SMI received fragmented services and were not 
provided affordable housing options (Carling, 1993; Räsänen et al., 2000), and large numbers 
became homeless (Lamb & Bachrach, 2001). Baum and Burnes (1993) estimated that as much as 
one half of all individuals who are homeless have some type of SMI, a vulnerable group at risk 
of deteriorating quickly from improper treatment and the effects of substance use (Lamb & 
Bachrach, 2001). Alcohol and illicit drug use contribute to medication nonadherence and can 
exacerbate symptoms, which may result in bizarre behavior; and individuals with SMI who 
exhibit odd behavior in public are often inappropriately arrested and incarcerated (Lamb & 
Bachrach, 2001).   
 In the 1970s and 1980s, due to major policy changes and inadequate community-based 
treatment, the criminal justice system increasingly assumed the role of state hospitals (Borzecki 
& Wormith, 1985). In fact, Foderaro (1994) reported that by the 1990s, there were more 
individuals with SMI in jails and prisons than in psychiatric hospitals. The criminalization of 
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mental illness is a complex and multifaceted contemporary public health issue, and changes on 
multiple levels must be implemented to ensure that those with SMI are provided with appropriate 
community-based treatment and support (Lamb & Bachrach, 2001). In addition, Stuart and 
Arboleda-Flórez (2012) assert that challenging mental health stigma is a public health priority 
and that initiatives to redress discrimination are needed to ameliorate existing social disparities.  
 In sum, thought disorders can be debilitating for affected individuals, so practitioners 
must be knowledgeable about the prevalence, diagnostic criteria, effective pharmacological and 
psychosocial interventions, and relevant risk factors. Treatment of individuals with schizophrenia 
and other thought disorders typically involves antipsychotic medications (Chien & Yip, 2013); 
however, second-generation antipsychotics cause a variety of metabolic side effects (e.g., weight 
gain, dyslipidemia), which may lead to the development of chronic health diseases (Tandon et 
al., 2008). These side effects, in addition to other factors affecting health status, result in 
individuals with thought disorders being disproportionately affected by comorbid physical health 
conditions.  
Comorbidity, Risk Factors, and the Importance of Screening 
 
It is well established that individuals with SMI live, on average, 25 years less than 
individuals without SMI (Parks, Svendsen, Singer, & Foti, 2006). According to Parks et al. 
(2006), preventable physical health conditions (e.g., cardiovascular disease, pulmonary disease, 
infectious disease) account for 60% of early deaths in individuals diagnosed with schizophrenia, 
and several of the risk factors (e.g., smoking, alcohol consumption, drug use, poor nutrition, 
sedentary lifestyle) that contribute to these physical health conditions are modifiable (Parks et 
al., 2006). Efforts have been made to address this public health crisis through federally-supported 
grants (Scharf et al., 2013), discussed below. 
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Comorbidity Among Individuals With Thought Disorders 
 
Extant research shows that certain cardiometabolic conditions (e.g., obesity, 
hypertension, high blood sugar, elevated triglyceride [TRI] levels, reduced high-density 
lipoprotein [HDL] levels) increase an individual’s chances of developing diabetes, heart disease, 
or stroke (De Hert et al., 2011). This section reviews statistics drawn from a variety of sources 
that describe the co-occurrence of physical health conditions and diseases among individuals 
with SMI, with a special focus on individuals with schizophrenia and other thought disorders. 
The prevalence rates of comorbid health conditions and largely preventable diseases are 
higher among individuals with schizophrenia and schizoaffective disorder. Correll et al. (2010) 
conducted a large-scale study of 10,084 individuals with mental illness and found that among 
individuals with schizophrenia, 79% were overweight or obese, 52% had metabolic syndrome, 
51% had hypertension, 40% had hypertriglyceridemia, 37% had hyperglycemia, and 30% had 
dyslipidemia. The National Comorbidity Survey Replication (N=9,282) determined that 
approximately 68% of adults with mental disorders, including those with diagnoses on the 
schizophrenia spectrum, had at least one co-occurring physical health condition (Alegria, 
Jackson, Kessler, & Takeuchi, 2003). In a large-scale, population-based study, Carney, Jones, 
and Woolson (2006) found that individuals with schizophrenia and schizoaffective disorder were 
significantly more likely than control group participants (with no mental disorders) to have one 
or more chronic health conditions, and of the 1,074 participants with thought disorders, 33% had 
three or more chronic health conditions. Carney et al. (2006) further reported that individuals 
with thought disorders were more likely than controls to experience health conditions across 
multiple organ systems, as well as experience co-occurring substance abuse and dependence (i.e., 
alcohol, illicit drugs, nicotine). 
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Smaller-scale studies have demonstrated similar results. For example, Baughman et al. 
(2016) compared health information from 203 adults with SMI to similar data collected from a 
matched sample of adults without SMI and found that individuals with SMI had higher 
prevalence rates of 7 out of 9 chronic diseases (i.e., chronic pain, respiratory problems, arthritis, 
cardiovascular disease, headaches, diabetes, ulcers in the stomach/intestine; Baughman et al., 
2016). Jones et al. (2004) examined a subsample of Medicaid claims of adults diagnosed with 
SMI (e.g., schizophrenia, schizoaffective disorder) to determine the prevalence of comorbid 
physical conditions. Of the 147 cases reviewed, 75% of participants had at least one chronic 
health condition, and 50% had two or more chronic health conditions (Jones et al., 2004). The 
most common chronic health problem was pulmonary illness, at 31% (Jones et al., 2004).  
Diabetes is a notable problem among persons with schizophrenia due to obesity. These 
individuals are 2 times more likely than the general population to develop diabetes, and they are 
more likely to develop the condition at a younger age (De Hert et al., 2010). Additionally, 
individuals with schizophrenia (and other thought disorders) and comorbid diabetes experience a 
more complicated course of the disease than is experienced by the general population (Carney et 
al., 2006). This disproportionate rate of diabetes likely can be explained by obesity, which often 
predicts the development of the disease (Gough, 2005).  For example, Coodin (2001) showed 
that persons with schizophrenia are 2.8 to 3.5 times more likely than the general population to be 
obese. In addition, a study of 262 adults with SMI (i.e., schizophrenia, schizoaffective disorder, 
bipolar disorder) found that individuals with schizoaffective disorder had the highest rates of 
obesity, after controlling for relevant demographic characteristics (Chouinard et al., 2016).  
Descriptive studies of individuals with comorbid mental disorders and physical health 
conditions have examined differences across gender and race. Lemieux, Richards, Hunter, and 
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Kasofsky (2015), for example, examined individuals (N=125) receiving integrated health 
services at 3 different CMH centers and determined that female participants had significantly 
more comorbid physical health conditions (0.86) than male participants (0.53). In addition, 
women reported comorbid cardiac disease at a rate 4 times that of men (at 22.1% and 5%, 
respectively; Lemieux et al., 2015). Gleason et al. (2014) also examined gender differences 
between men (N=167) and women (N=144) receiving integrated services in a CMH setting. 
Analyses showed that female participants had significantly higher waist circumference and body 
mass index (BMI) scores, as compared to men (Gleason et al., 2014). Although more men than 
women had hypertension, men and women were equally at risk for developing diabetes and 
metabolic syndrome (Gleason et al., 2014).  
Racial differences also emerged in the study by Lemieux et al. (2015). Blacks were more 
likely than Whites to have more comorbid conditions, as well as show higher BMI and blood 
pressure (BP) scores (Lemieux et al., 2015). Conversely, Whites had higher low-density 
lipoprotein (LDL) and TRI scores than Blacks (Lemieux et al., 2015).  
Risk Factors for Developing Comorbid Health Conditions  
This section provides an overview of identified factors that place individuals with SMI at risk for 
developing physical health conditions, namely smoking, substance use, poor nutrition, sedentary 
lifestyle, and medication side effects. Research shows that the majority of these risk factors are 
modifiable (Parks et al., 2006).  
Smoking. According to the Centers for Diseases Control and Prevention (CDC, 2013), 
smoking is the primary cause of preventable diseases and deaths in the United States. Results 
from the 2009-2011 National Survey on Drug Use and Health revealed that 36% of adults with 
mental illness smoke as compared to 21% of adults without mental illness (SAMHSA, 2011). 
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Results also showed that smokers with mental illness were less likely to quit than smokers 
without mental illness, despite the fact that many indicated a desire to do so (SAMHSA, 2011). 
Hartz et al. (2014) conducted a large-scale study of smoking and compared individuals 
with severe psychotic disorders (i.e., bipolar disorder with psychosis [N=1,507], schizoaffective 
disorder [N=2,037], schizophrenia [N=5,586]) to individuals without the conditions (N=10,311). 
Results showed that individuals with psychotic disorders were far more likely than control 
participants to have smoked at least 100 cigarettes in a lifetime (bipolar disorder with psychosis 
[74%], schizoaffective disorder [79%], schizophrenia [74%], control participants [33%]) and to 
be daily smokers (bipolar disorder with psychosis [71%], schizoaffective disorder [77%], 
schizophrenia [72%], control participants [29%]; Hartz et al., 2014). Dickerson et al. (2013) 
examined 991 individuals with schizophrenia (N=421), bipolar disorder (N=126), and no 
psychiatric illnesses (N=444) and found that 64% of if the individuals with schizophrenia, 44% 
of the individuals with bipolar disorder, and 19% of the individuals without psychiatric illnesses 
smoked. Subsequent analyses determined that the following characteristics were strongly 
associated with higher rates of cigarette consumption among those with SMI: male gender, co-
occurring substance use, White race, and lower education level (Dickerson et al., 2013).  
Studies have attempted to determine the cause of increased rates of smoking among 
individuals with schizophrenia and other thought disorders. Miller (1977) hypothesized that 
individuals who take first-generation antipsychotics smoke to reduce extrapyramidal side effects 
associated with the medications. Higher rates of smoking might also be explained by central 
nervous system tolerance, associated with long-term use of nicotine (Adler et al., 1998). 
Additionally, some individuals might be seeking the reduction of anxiety or elevation of mood 
that can result from nicotine usage (Kirch, Gerhardt, Shelton, Freedman, & Wyatt, 1987). 
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Finally, because persons with schizophrenia have problematic function of nicotinic acetylcholine 
receptors, these individuals might smoke to generate a pharmacodynamics effect (i.e., activation 
of neuronal receptors by the substance; Adler et al., 1998). 
Alcohol and Other Substance Use. According to SAMHSA (2016), approximately 1% 
of adults in the United States (an estimated 2.3 million) have co-occurring SMI and SUD. 
Although the use of certain substances is known to ameliorate negative symptoms of psychotic 
disorders (e.g., anhedonia, boredom; Batel, 2000), individuals with co-occurring SUD are more 
prone to adverse events, such as exacerbated psychotic symptoms, poorer medication 
compliance, homelessness, and a variety of preventable physical health problems (Dixon, 1999).  
 Dixon (1999) suggested that roughly 50% of all individuals with schizophrenia struggle 
with co-occurring SUD, and most frequently misuse alcohol and marijuana. Hartz et al. (2014) 
examined 5,586 individuals with schizophrenia and found that 28% consumed more than 4 
drinks a day, 43% smoked marijuana more than 21 times a year, and 35% had used other 
recreational drugs more than 10 times during their lifetime. However, rates were slightly higher 
for participants diagnosed with schizoaffective disorder (N=2,037): 29% consumed more than 4 
drinks a day, 53% smoked marijuana more than 21 times a year, and 52% had used other 
recreational drugs more than 10 times during their lifetime (Hartz et al., 2014). 
 According to Hartz et al. (2014), rates of substance use vary markedly across race and 
gender in the general population. For example, among participants in the control group 
(N=10,311), Whites had higher rates of substance use than Hispanics and Asians, and men had 
higher rates than women. However, these demographic differences were not evident among 
individuals with severe psychotic disorders, whose rates of use were relatively consistent across 
race and gender (Hartz et al., 2014).  
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Poor Nutrition. According to Peet (2003), numerous studies have linked poor nutrition 
to the development of heart disease, diabetes, and several cancers, and it is well known that 
many persons with schizophrenia have substandard diets. Dipasquale et al. (2013) reviewed 31 
studies of nutrition among individuals with schizophrenia and found that the majority of 
participants consumed large amounts of saturated fats and small amounts of fiber and fruit. 
Strassnig, Brar, and Ganguli (2003) administered a nutrition assessment to 146 psychiatric 
patients with schizophrenia, schizoaffective disorder, and other psychotic disorders and 
compared their responses to an age-adjusted group from the general population. Results revealed 
that percentages of intake for protein, carbohydrates, and fat were not different between the two 
groups; however, individuals with schizophrenia ate higher quantities of food (Strassnig et al., 
2003).  
Studies have attempted to determine the reasons for dietary differences between 
individuals with schizophrenia and the general population. Suvisaari, Keinänen, Eskelinen, and 
Mantere (2016) suggested that poverty could be a major barrier to obtaining higher-quality 
foods. Further, atypical antipsychotics might increase hunger sensations, which ultimately results 
in overeating (Blouin et al., 2008).  
Sedentary Lifestyle. According to Mokdad, Marks, Stroup, and Gerberding (2004), low 
levels of physical activity and poor diet are the second leading causes of death in the United 
States and may become the leading causes of death in the country. Rates of chronic diseases are 
prevalent among individuals with SMI; thus, this population could experience substantial 
benefits from increased levels of physical activity (Daumit et al., 2005). Blair et al. (1995) found 
that even after years of inactivity, people can significantly improve their health by increasing 
their levels of exercise.  
	 25	
Galletly et al. (2012) collected data from 1,825 outpatients, including individuals with 
schizophrenia (N=857) and schizoaffective disorder (N=293), and found that almost all (96.7%) 
participants engaged in low (63.1%) or very low (33.6%) levels of physical activity. Gender 
differences in level of physical activity were not evident; however, younger individuals were 
more likely to report low levels of physical activity, and older adults were more likely to report 
very low levels of physical activity (Galletly et al., 2012). Daumit et al. (2005) conducted a 
smaller-scale study comparing 185 individuals with SMI (including individuals with 
schizophrenia and schizoaffective disorder) to a subset of individuals from the National Health 
and Nutrition Examination Survey (N=2,705). Results showed that over one fourth of individuals 
with SMI (25.7%) engaged in no physical activity during the previous month, as compared to 
controls, at 17.5% (Daumit et al., 2005). 
Researchers have attempted to determine the reason for low levels of physical activity 
among individuals with thought disorders. Negative symptoms might inhibit the desire to 
maintain adequate levels of physical activity (Lambert, Velakoulis, & Pantelis, 2003). Suvisaari 
et al. (2016) suggested that individuals with schizophrenia might be less able to afford gym 
memberships (due to low socioeconomic status) and that this obstacle might also contribute to 
subpar levels of physical activity levels.  
Medications. Second-generation antipsychotics significantly increase the likelihood of 
gaining weight and developing diabetes and dyslipidemia, and specific agents (e.g., clozapine 
and olanzapine) are associated with even higher rates of these metabolic conditions (Tandon et 
al., 2008). Allison et al. (1999) conducted a meta-analysis of 81 studies to determine the impact 
of various antipsychotic medications on weight after 10 weeks of standard dosages of included 
agents. Results revealed that the first-generation drug molindone was associated with a mean 
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weight reduction of 0.39 kg; however, the other analyzed conventional antipsychotic, 
thioridazine, was associated with a mean weight gain of 3.19 kg (Allison et al., 1999). All 
atypical antipsychotics included in the research synthesis were associated with weight increases: 
clozapine (4.45 kg), olanzapine (4.15 kg), sertindole (2.92 kg), risperidone (2.10 kg), and 
ziprasidone (0.04 kg).  
Although first-generation medications are less likely to cause these adverse metabolic 
effects (Smith et al., 2008), physicians might be hesitant to prescribe them because of 
extrapyramidal side effects and risk of developing tardive dyskinesia (Tandon et al., 2008). 
According to Keating et al. (2017), consideration of all medication side effects is the most 
important factor in selecting an antipsychotic medication.  
The Importance of Screening  
According to Parks et al. (2006), early detection is key to reducing rates of 
cardiometabolic conditions among individuals with SMI. Providers should systematically track 
mechanical (i.e., BMI, systolic BP, diastolic BP) and laboratory (i.e., blood glucose, HDL, LDL, 
TRI) health indicators in order to effectively monitor the physical health of individuals with SMI 
(Parks, Radke, Mazade, & Mauer, 2008). BMI is used to detect obesity, a condition that leads to 
increased risk of diabetes, heart disease, and hypertension (Parks et al., 2008). Monitoring BP is 
important, as higher BP predisposes individuals to developing heart disease, hypertension, and 
stroke (Parks et al., 2008). Increased HDL is associated with lower risk of heart disease and 
serves as a protective factor; conversely, higher LDL and TRI are associated with diabetes, heart 
disease, and obesity (Parks et al., 2008). In addition to routine monitoring, Parks et al. (2008) 
also noted the importance of gathering family and personal history of cardiometabolic 
conditions, along with personal history of alcohol, drug, and tobacco use.   
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Screening is important for primary, secondary, and tertiary health interventions (Parks et 
al., 2008). Individuals without cardiometabolc conditions should be screened regularly and 
encouraged to participate in activities that prevent the development of these conditions (Parks et 
al., 2008). When cardiometabolic conditions are present, individuals with SMI should be linked 
to specific wellness interventions to improve their prognosis and to prevent the development of 
chronic diseases (e.g., diabetes, hearth disease, or stroke; Parks et al., 2008). Finally, individuals 
diagnosed with comorbid diseases should be frequently monitored in order to restore functioning 
and to prevent the development of disease-related complications (Parks et al., 2008). 
Treatment Utilization and Barriers Among Individuals with Thought Disorders 
Despite the high prevalence rates of physical health conditions among individuals with 
SMI, they are less likely to visit physicians for routine medical care than the general population 
(Druss & Walker, 2011; Lu et al., 2008; Roesenberg et al., 2007). Cradock-O’Leary, Young, 
Yano, Wang, and Lee (2002) reviewed 175,653 patient records from the Department of Veterans 
Affairs (VA) databases to analyze medical care usage and found that individuals with SMI had 
far fewer medical visits than those without any type of mental illness. Young male adults with 
schizophrenia, in particular, had an elevated risk for not receiving medical care (Cradock-
O’Leary et al., 2002). Correll et al. (2010) offered free metabolic screenings to 10,084 patients 
with mental illness, including schizophrenia, in order to determine rates of undertreatment of 
medical conditions. Of the adult participants with schizophrenia, 57% of those with 
dyslipidemia, 56% of those with metabolic syndrome, 49% of those with hypertension, and 41% 
of those with diabetes reported having received no treatment for the conditions (Correll et al., 
2010). 	
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Extant research indicates that individuals with SMI tend to overuse emergency services 
for medical care (Hackman et al., 2006; Salsberry, Chipps, & Kennedy, 2005) because of 
inadequate access and numerous barriers to routine and preventative care (Parks et al., 2006). 
Miller et al. (2003), for example, surveyed 59 CMH clients about access to primary care and the 
quality of that care and found that almost two thirds (63%) could not identify the names of their 
primary care providers offhand. Of the individuals who did have a consistent source of primary 
care (14%), many reported relying on emergency services for their physical health issues (Miller 
et al., 2003). Finally, for those who reported receiving some type of primary care, scores on the 
Primary Care Assessment Tool showed that participants were receiving less than ideal care, in 
that mental health providers often failed to ask about physical conditions, and, conversely, 
medical providers failed to ask about mental health issues (Miller et al., 2003).  
Individual factors also contribute to disparities in health care utilization (Druss & Walker, 
2011). Paranoia and negative symptoms (e.g., amotivation) may prevent individuals with thought 
disorders from obtaining needed medical treatment (Parks et al., 2006). Others are hesitant to 
seek treatment out of fear of judgment (Wahl, 1999). Socioeconomic circumstances may also 
play a role. Studies by Gleason, Truong, Biebel, Hobart, and Kolodziej (2017) and Thomas 
(2017) showed that access to transportation was associated with treatment engagement.  
Providers also create barriers to adequate primary care in both physical and behavioral 
health settings. Druss and Walker (2011) suggested that stigma surrounding mental illness might 
discourage primary health providers from treating persons with SMI. Conversely, psychiatrists 
might feel ill prepared to treat the various medical needs of people with SMI (Druss & Walker, 
2011). Gleason et al. (2017) further found that inconvenient appointment times were also barriers 
to treatment engagement. However, Parks et al. (2006) maintained that the principal barrier to 
	 29	
satisfactory primary care is the poor coordination between multiple providers that operate in 
separate systems of health care. 
The Importance of an Integrated Health Approach 
An integrated health approach directly addresses fragmentation between separate systems 
of care. Integrated care, broadly speaking, refers to health care arrangements that combine 
primary and mental health services in the same setting (Scharf et al., 2013). According to 
Gerrity, Zoller, Pinson, Pettinari, and King (2014), integrated PBHC programs use different 
strategies to coordinate physical and mental health care services for persons with multiple 
chronic conditions, including SMI. There are several models of integrated care: coordinated, co-
located, and fully integrated (Heath, Wise, Romero, & Reynolds, 2013). Coordinated care 
involves communication between providers of separate facilities (Heath et al., 2013). This 
particular model of integration typically utilizes care managers who can provide outside referrals 
to clients, assist clients in connecting with external resources, and follow up with clients’ various 
providers (Druss & Walker, 2011). Co-located care involves the provision of physical health 
services in CMH centers or, conversely, mental health treatment in primary care clinics (Heath et 
al., 2013). This particular integrated PBHC model is a feasible alternative when full integration 
is not possible (Druss & Walker, 2011). Finally, fully integrated PBHC organizations, such as 
the VA (Druss & Walker, 2011), have the capacity to provide all necessary physical and mental 
health services to individuals with comorbid conditions (Heath et al., 2013).  
Little research has evaluated interventions to improve the physical health of persons with 
SMI (Druss, Rohrbaugh, Levinson, & Rosenheck, 2001; Kilbourne et al., 2008), and most of the 
existing research on integrated treatment approaches has been conducted within fully integrated 
organizations, such as the VA (Druss & Walker, 2011). In 2015, approximately two thirds of 
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adults with SMI reported receiving behavioral health services during the previous year (65.3%; 
SAMHSA, 2016). Individuals with SMI are more likely to seek health care services through 
CMH centers, thus, these agencies are the ideal locations to provide coordinated care (Druss et 
al., 2010).  
Druss et al. (2008) surveyed CMH centers across the country to assess their capacity to 
provide primary care services to clients.  Of the 181 CMH centers that responded, the majority 
routinely screened for hypertension (80%) and for obesity (72%), but less than half screened for 
diabetes (47%) and dyslipidemia (44%). Other sites referred clients out for medical screenings 
(Druss et al., 2008). Although well over two thirds (71%) of the CMH centers reported an ability 
to provide on- or off-site medical screenings, only about half (51%) reported having the capacity 
to provide treatment for identified medical problems (Druss et al., 2008). Respondents reported 
several barriers to provision of medical services, including issues around reimbursement (72%), 
limited staff (69%), physical space limitations (61%), and a lack of community referral options 
(56%; Druss et al., 2008).  
SAMHSA funded the Primary and Behavioral Health Care Integration (PBHCI) grants 
program to improve the overall health of individuals with SMI via co-location of various primary 
care services in CMH settings (Scharf et al., 2013). CMH centers that received grant funding 
were required to provide physical health screenings and referrals, develop a health needs and 
outcomes tracking system, offer care management services, and implement wellness programs 
(Scharf et al., 2013). In an uncontrolled evaluation, the RAND Corporation assessed the success 
of the PBHCI grants program and reported many accomplishments, including the establishment 
of multidisciplinary teams that offered a variety of wellness programs (Scharf et al., 2013). 
However, grantees also experienced several unforeseen challenges (e.g., low consumer 
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enrollment, issues with financial sustainability, communication problems between team 
members; Scharf et al., 2013). Nevertheless, Scharf et al. (2013) concluded that the PBHCI 
program, overall, was successful in creating necessary services for underserved and vulnerable 
community-based populations, and they suggested that efforts should be made to increase 
consumer access to integrated PBHC services and that strategies should be developed to improve 
sustainability.  
Although efforts have been made to implement integrated services in CMH settings, few 
studies have evaluated the impact of these programs on health outcomes (Gerrity et al., 2014). 
The Primary Care Access and Referral (PCARE) study by Druss et al. (2010) randomly assigned 
CMH clients to either care management services (N=205) or to usual care (N=202). Nurse care 
managers educated treatment group participants about their medical conditions, provided them 
with specialty referrals, and created action plans with them mapping out medical care and 
lifestyle change goals. At 12 months out, well over half of the participants in the care 
management intervention group received primary services (58.7%), a rate almost twice that of 
participants in the control group (21.8%; Druss et al., 2010). Lab work indicated that the risk of 
developing cardiovascular disease decreased by 11.8% in the treatment group, but increased by 
19.5% in the control group. Additionally, a greater number of previously undiagnosed physical 
health conditions were discovered in the care management group (Druss et al., 2010). These 
latter results are promising in terms of the potential effectiveness of co-located care, given that 
most CMH centers do not have the resources to provide fully integrated services.  
In an uncontrolled evaluation study, Putz et al. (2015) collected longitudinal data from a 
sample of 169 adults with SMI receiving a collaborative care intervention at a CMH center. 
Participants received comprehensive health assessments upon program entry, were assigned a 
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case manager, and were offered a variety of wellness programs. At 6 months out, significant 
improvements in health outcomes were observed, including weight loss, decreases in smoking 
and LDL, and increases in HDL (Putz et al., 2015). Results demonstrated by Druss et al. (2010) 
and Putz et al. (2015) suggest that co-located integrated health approaches resulted in improved 
outcomes for CMH clients with SMI.  
SMI, Treatment Disengagement, and Treatment Retention 
Treatment engagement is critical for individuals with SMI, as those who drop out are at 
greater risk of experiencing increased morbidity (Davis et al., 2012), intensified psychiatric 
symptoms, frequent hospitalizations, homelessness, legal problems, and suicidal ideation (Dixon 
et al., 2009; Fischer et al., 2008). According to Druss and Walker (2011), ongoing contact with 
providers helps individuals with SMI to manage symptoms and medications. Adair et al. (2005) 
conducted a longitudinal study of 486 adults with SMI to examine the relationship between 
continued care and health outcomes and found that treatment continuity was associated with 
better quality of life, improved functioning, reduced symptom severity, and increased service 
satisfaction. Adair et al. (2005) suggested that efforts should be made in health settings to 
improve continuity of care, which was defined by Bachrach (1981) as “a process involving the 
orderly, uninterrupted movement of patients among the diverse elements of the service delivery 
system” (p. 1449).  
The majority of individuals with SMI often do not complete the recommended course of 
treatment (Wang, 2007; Wang et al., 2000). Olfson et al. (2009) examined a subsample of 
individuals (N=1,664) with various psychiatric diagnoses from the National Comorbidity Survey 
Replication in order to determine patterns and predictors of primary care and mental health 
treatment dropout. Results indicated that over one fifth of participants (22.4%) dropped out of 
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treatment prematurely and that individuals were more likely to discontinue primary care services 
(31.6%) than mental health services (15.1%; Olfson et al., 2009). Analyses revealed that Blacks 
were more likely than Whites to discontinue treatment and that younger individuals were more 
likely than older individuals to withdraw from care (Olfson et al., 2009). Education level and 
employment status, however, were negatively associated with treatment disengagement (Olfson 
et al., 2009).  
Kreyenbuhl, Nossel, and Dixon (2009) also sought to determine patterns and predictors 
of treatment dropout. However, unlike Oflson et al. (2009), Kreyenbuhl et al. (2009) exclusively 
focused on mental health treatment disengagement among individuals with schizophrenia. A 
comprehensive literature review revealed that up to one third of those with schizophrenia 
discontinue treatment prematurely (Kreyenbuhl et al., 2009), a rate substantially higher than the 
range reported by Oflson et al. (2009; 15.1%-31.6%). Kreyenbuhl et al. (2009) noted that 
younger age, male gender, minority group membership, and lower levels of functioning were 
positively associated with treatment disengagement and that individuals with early-onset 
psychosis and co-occurring SUD were particularly at risk of discontinuing care. Finally, 
Kreyenbuhl et al. (2009) found that clients’ perspectives about the care they received also 
impacted treatment dropout, in that individuals who felt unheard were more likely to disengage 
from treatment.  
A recent study showed that treatment reengagement is associated with decreased 
mortality rates (Davis et al., 2012). In a large-scale study by Davis et al. (2012), VA staff 
members contacted 3,306 veterans with SMI who had failed to return for follow-up visits for at 
least 1 year in an attempt to reengage them in care. Of those contacted, approximately 72% 
(N=2,375) resumed treatment (Davis et al., 2012). Individuals who declined to return reported 
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that they did not perceive a need for care, they were dissatisfied with VA services, they faced 
transportation barriers, or several of these reasons (Davis et al., 2012). Clients who restarted 
treatment were almost 6 times less likely to experience early mortality than individuals who did 
not return for care (Davis et al., 2012).  
Few studies have examined retention rates in integrated health programs. Data collected 
from 56 federally-funded PBHC programs revealed that among the 25,648 enrollees, roughly 
22% (N=5,755) terminated treatment at around 7 months from program enrollment (Scharf et al., 
2013). However, the reported rate of disengagement did not include program participants who 
disengaged from care immediately following preliminary enrollment interviews (Scharf et al., 
2013). Two smaller-scale studies assessing PBHC outcomes (Druss et al., 2010; Putz et al., 
2015) reported client retention rates as part of their evaluations. Among 205 CMH clients who 
received care management services in Druss et al.’s (2010) PCARE study, 78% remained in 
treatment at 12-month follow up; however, among those who received usual care (N=202), 
69.3% were retained at 12 follow up. In Putz et al.’s (2015) evaluation of 169 CMH clients 
receiving a collaborative care intervention, 86.9% (N=147) were retained at 6 months, and 70.4% 
(N=119) were retained at 12 months out.  
Thomas (2017) focused specifically on correlates of treatment retention among 
individuals with SMI, including individuals with thought disorders (N=119) and mood disorders 
(N=192), receiving integrated services in a CMH setting. Of the 359 participants included in the 
study sample, approximately half (47.1%) were retained at 6 months, while only 29.2% were 
retained at 12 months (Thomas, 2017). Analyses revealed that reliable access to transportation, 
abstaining from substance use, and retention at 6 months were associated with 12-month 
retention (Thomas, 2017). Further, individuals with thought disorders were more likely than 
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individuals with mood disorders to be retained at 12 months (at 31.1% and 25.5%, respectively; 
Thomas, 2017).  
Lemieux et al. (2017) expanded upon the research of Thomas (2017). Clinical data from 
446 PBHC program clients (148 with thought disorders and 240 with mood disorders) were 
analyzed to examine predictors of treatment retention at 6 months (Lemieux et al., 2017). Results 
of multivariate analyses showed that 6-month retention was associated with type of disorder, 
overall health, greater number of prescribed medications, laboratory data at baseline, having a 
primary care provider, reliable transportation, and living alone (Lemieux et al., 2017). Among 
these latter correlates, only two predicted retention in care at 6 months (Lemieux et al., 2017). 
The number of medications prescribed at baseline and having a thought disorder increased the 
likelihood of retention (Odds Ratios = 1.20 and 1.99; Lemieux et al., 2017). 
Summary and Implications 
SMI affects 4% of the U.S. population, notably compromising the functioning and ability 
of those impacted (SAMHSA, 2016). Thought disorders are especially debilitating, and people 
with these conditions, such as schizophrenia, face a variety of complicated psychiatric symptoms 
(APA, 2013) and also stigma (Stuart & Arboleda-Flórez, 2012). Further, individuals with 
schizophrenia have higher rates of early mortality than the general population, with research 
showing that approximately 60% of early deaths among individuals diagnosed with thought 
disorders are preventable (Parks et al., 2006). Efforts have been made to address the health 
disparities faced by individuals with SMI through federally-supported grants (Scharf et al., 
2013); however, scant research has rigorously evaluated the effectiveness of integrated programs 
in CMH settings (Gerrity et al., 2014), and even fewer studies have specifically analyzed 
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treatment retention and correlates of treatment continuation among integrated PBHC program 
enrollees (Thomas, 2017; Lemieux et al., 2017). 
Treatment engagement is critical, with a large body of research indicating that continued 
contact with providers helps individuals with SMI manage their symptoms (Druss et al., 2011). 
In addition, reengagement with services following a period of disengagement is associated with 
considerably lower rates of premature mortality (Davis et al., 2012). Research undertaken with 
diverse populations of clients with SMI indicates that treatment retention is associated with 
better outcomes, in terms of symptomology and functioning (Adair et al., 2005), and health and 
wellbeing (Adair et al., 2005). Studies have also shown that certain sociodemographic (e.g., 
employment status; Olfson et al., 2009), psychosocial (e.g., higher levels of functioning; 
Kreyenbuhl et al., 2009), health (e.g., abstinence from substance use; Kreyenbuhl et al., 2009), 
and treatment-related characteristics (e.g., access to transportation; Davis et al., 2012) are 
associated with retention among clients with SMI. However, only 2 studies specifically 
examined correlates of treatment retention among CMH clients in integrated health programs. 
Thomas (2017) found that the strongest predictor of treatment retention at 12 months was 
retention at 6 months. Further, individuals with thought disorders were more likely than those 
with mood disorders to be retained at 12 months, at 31.1% and 25.5%, respectively (Thomas, 
2017). Lemieux at al. (2017) used a multivariate approach to extend the work of Thomas (2017) 
and found that among the 7 correlates of treatment retention, 2 health-related characteristics 
predicted 6-month retention. Individuals with thought disorders were almost twice as likely as 
those with mood disorders to be retained in care at 6 months (Lemieux et al., 2017). Frequency 
of medications also slightly increased the likelihood of 6-month retention (Lemieux et al., 2017).   
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The few longitudinal evaluations of integrated PBHC programs indicate that CMH clients 
who are retained in care show improvements on critical biomarkers of health and other measures 
of psychosocial functioning and wellbeing (Druss et al., 2010; Putz et al., 2015). However, prior 
to this analysis, no study to date had examined the extent to which CMH clients diagnosed with 
thought disorders in integrated PBHC programs showed improvement on critical health and 
psychosocial outcomes. As systems of care move toward greater integration (Gerrity et al., 
2014), evaluators are better positioned to include objective biomarkers of health, consistent with 
recommendations by Parks et al. (2006; 2008), and empirically-supported psychosocial measures 
when examining outcomes among individuals with SMI. The current study sought to identify and 
describe health and psychosocial improvements among individuals with thought disorders 
receiving integrated services in CMH settings, as well as identify the sociodemographic, health-
related, and treatment-related characteristics that are associated with improvement. This study 
also sought to increase existing knowledge about persons with thought disorders receiving 
integrated PBHC services by examining relevant correlates (i.e., sociodemographic, health, 










CHAPTER 3: CONCEPTUAL FRAMEWORK 
This section outlines the purpose of the current study, the research questions that were 
investigated, and definitions of relevant key terms. 
Purpose  
The current study is an exploratory secondary analysis that is longitudinal in scope, as 
outcome measures were re-administered to particular participants at a later time (6 months; 
Caruana, Roman, Hernández-Sánchez, & Solli, 2015). It examined the sociodemographic, health, 
health-risk, and treatment-related characteristics that are associated with health and psychosocial 
improvements among individuals with thought disorders. The present study used preexisting data 
collected at baseline and follow up from clients enrolled in integrated PBHC programs at three 
CMH centers in Louisiana. The data include information collected from surveys and objective 
health-indicator scores recorded in clinical records. 
Research Questions 
The current correlational study focused on the following questions:  
1. What are the sociodemographic, health, health-risk, treatment-related characteristics of 
individuals with thought disorders receiving integrated PBHC in CMH settings?  
2. What proportion of participants with thought disorders is retained at 6 months out?  
3. Do participants with thought disorders show improvement from baseline to 6 months out 
on relevant health and psychosocial characteristics?  
4. Are sociodemographic, health, health-risk, and treatment-related factors associated with 
improvements in psychosocial characteristics from baseline to 6 months out?  
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5. Are sociodemographic, relevant health, health-risk, and treatment-related characteristics 
associated with clinically meaningful improvements on objective measures of health from 
baseline to 6 months out?  
Key Terms  
This section defines key terms included in the research questions. Chapter 4 focuses on 
methodology and describes, in detail, how each variable was measured. 
Sociodemographic Characteristics  
Sociodemographic characteristics for the current study include age, gender, race, 
employment status, disability status, living arrangement, and education level. All of the 
aforementioned characteristics were self-reported by participants at baseline. Participants 
reported their age, gender, and race to nurse care managers upon enrollment. Employment status 
includes two categories, employed and unemployed. Employed participants reported working 
either full time or part time. Unemployed participants reported that they were looking for work, 
volunteering, retired, or not looking for work. Disability status refers to whether a participant 
was receiving disability benefits. Living arrangement is defined as whether participants lived in 
their own house or apartment or lived with someone else 30 days prior to enrollment. Finally, 
education level is defined as whether a participant had less than a high school education or a high 
school education or greater. 
Health Characteristics 
Health characteristics for the current study include the total number of prescribed 
medications, whether or not antipsychotic medications were prescribed at baseline, and self-
assessed health. Prescribed medications include the frequency and type of all medications 
prescribed to participants that were recorded by nurse care managers at baseline, including those 
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for both mental disorders and comorbid conditions. Self-assessed health is participants’ self-
reported perceptions of physical health, as measured with a general self-rated health (GSRH) 
question. Health-risk characteristics include participants’ self-reported use of alcohol, tobacco, 
and illicit or non-prescribed drugs, as well as self-reports indicating whether participants had 
ever been diagnosed with hypertension, diabetes, and heart disease. 
Treatment-Related Characteristics 
Treatment-related characteristics include access to reliable transportation, the number of 
clinic services received, whether participants had a primary health care provider at baseline, and 
clinic site. Reliable transportation reflects participants’ self-reports of having access to reliable 
transportation. Number of clinic services is defined as the total number of health and mental 
health services (e.g., case management, treatment planning, primary care) received by 
participants, as recorded by nurse care managers. Primary health care provider at baseline refers 
to whether participants reported the name of a primary care physician at baseline, as recorded by 
nurse care managers. Finally, clinic site refers to 1 of 3 CMH sites where participants were 
receiving integrated PBHC services.   
Improvement in Psychosocial Characteristics 
Psychosocial characteristics include level of functioning, level of social support, and 
severity of symptomology. Level of functioning is participants’ self-reported perceptions of their 
day-to-day functioning, as measured with the 8-item Perception of Functioning (PF) scale. Level 
of social support reflects participants’ self-reported perceptions of social connectedness, which is 
measured with a 4-item Perception of Social Connectedness (PSC) scale. Finally, severity of 
symptomology is defined as participants’ self-reported feelings (e.g., nervous, hopeless, restless, 
depressed, worthless) during the 30 days prior to baseline and is assessed with the 6-item K6, a 
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measure of psychological distress. Improvement in psychosocial characteristics is defined as 
increases in both PF and PSC scale scores and a decrease in K6 scale scores. 
Improvement in Health 
Clinically-meaningful improvement in health is defined as moving out of risk, as defined 
by Center for Integrated Health Solutions (CIHS, 2013) guidelines, on any one of the mechanical 
(i.e., systolic and diastolic BP, BMI) biomarkers of health using scores recorded in participants’ 


















CHAPTER 4: METHODOLOGY 
This section describes the study sample, the original study from which the data were 
drawn, how study variables were measured, and data analysis methods. 
Design and Study Sample 
This exploratory secondary analysis examined existing data collected from participants 
with thought disorders who received integrated PBHC services in three different CMH settings. 
The sample includes all individuals with thought disorders and was drawn from an existing 
database of 1,270 participants with SMI (Lemieux et al., 2015). Participants in the original study 
were primarily low-income, uninsured, and eligible for government aid (Lemieux et al., 2015).  
Original Study 
In the original study (Lemieux et al., 2015), clients enrolled in three, publicly funded 
CMH centers were provided care management services, similar to those described in the PCARE 
study (Druss et al., 2010), from February 2012 to August 2015. Clients included those who 
lacked primary care providers, had not received a physical examination during the previous year, 
or presented with physical health complaints (Lemieux et al., 2015). Study participants were 
systematically screened by co-located nurse care managers who collected and recorded health 
information and provided primary care referrals, on-site wellness program referrals, prevention 
services, and education to enrolled clients (Lemieux et al., 2015).  
Nurse care managers administered the National Outcomes Measures Client-level 
Measures (NOMs) survey and the Integrated Health Program Baseline Physical Health Indicators 
Form (IHP-BPHIF) to program participants at the time of enrollment (Lemieux et al., 2015). 
Client data were de-identified, consistent with requirements of the Health Insurance Portability 
and Accountability Act, and entered by the evaluators into SPSS 21 for analysis (Lemieux et al., 
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2015). The original study was exempted from oversight by the Institutional Review Board of the 
researchers’ affiliated university (Lemieux et al., 2015). 
 The NOMs survey collects information about demographics, psychosocial functioning, 
housing, education, employment, criminal history, perception of care, and social connectedness. 
This measurement tool includes the Mental Health Statistics Improvement Program (MHSIP) 
scale, which was created by the National Association of State Mental Health Program Directors 
Research Institute (Jerrell, 2006). The IHP-BPHIF, developed by the study’s researchers and 
CMH staff members, gathers information about participants’ health insurance, physical and 
mental health diagnoses, prescription medications, health indicators, health-risk behaviors, 
personal and family history of medical conditions, and substance use history (Lemieux et al., 
2015).  
CMH clients enrolled in the Integrated Health Program (IHP) were reassessed at 6-month 
intervals until they were discharged (Lemieux et al., 2015). Nurse care managers re-administered 
the NOMs and also completed the Integrated Health Program Reassessment Health Indicators 
Form (IHP-RHIF) at every 6-month follow up (Lemieux et al., 2015). The latter form collects 
data on referral and wellness activities, health indicators, and medication changes (Lemieux et 
al., 2015).  
Instrumentation 
 Dependent Variables 
The dependent variables for the current study are improvement in health and 
improvement in psychosocial characteristics at 6 months out from baseline.  
Improvement in Health. Improvement in health was defined as moving from at risk to 
not at risk on any one of the mechanical (i.e., systolic and diastolic BP, BMI) health indicators, 
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using cut-off scores recommended CIHS (2013). Health indicators were dichotomized according 
to the recommended cut-off scores and coded as 0 (not at risk) and 1 (at risk).  
CIHS (2013) provided the following cut-off scores for the health indicators of interest: 
1. Systolic BP ≥ 130 = at risk  
2. Diastolic BP ≥ 85 = at risk  
3. BMI (%) ≤ 24 = normal (not at risk) 
BMI 25-29 = overweight (at risk) 
BMI 30-39 = obese (at risk) 
In the current study, BMI scores of 24 or lower were coded as 0 (not at risk). Scores 
higher than 25 were coded as 1 (at risk).  
Improvement in Psychosocial Characteristics. Improvement in psychosocial 
characteristics was defined an increase in PF scale scores, an increase in PSC scale scores, and a 
decrease in K6 scale scores. 
Level of functioning, defined as participants’ self-reported perceptions of their day-to-
day functioning, was measured with the 8-item PF scale on the NOMs (Schacht, 2001). The PF 
measure asks participants about their coping during the 30 days prior to study enrollment. For 
example, PF scale items include: “I deal effectively with daily problems,” and “I am able to deal 
with crisis.” A 5-point Likert scale is used to measure participants’ responses to each of the 8 
items, from strongly disagree (1) to strongly agree (5). Responses to the 8 items are summed to 
compute that person’s total daily functioning score, ranging from 8 to 40. Higher scores indicate 
higher levels of functioning. Lemieux et al. (2015) and Thomas (2017) reported Cronbach’s 
alphas of 0.76 and 0.79, respectively, indicating satisfactory internal consistency.  
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 Level of social support reflects participants’ self-reported perceptions of social 
connectedness, which was measured with the 4-item PSC scale on the NOMs (Schacht, 2001). 
The PSC measure asks participants about their personal relationships, excluding mental health 
providers, during the 30 days prior to study enrollment. PSC scale items include: “I am happy 
with the friends I have,” and “I feel I belong in my community.” A 5-point Likert scale is used to 
measure participants’ responses to each of the 4 items, from strongly disagree (1) to strongly 
agree (5). Responses to the 4 items are summed to compute that person’s total PSC score, 
ranging from 4 to 20. Higher scores indicate higher levels of perceived social support. Lemieux 
et al. (2015) and Thomas (2017) reported Cronbach’s alphas of 0.81 and 0.78, respectively, 
indicating adequate internal consistency.  
 Finally, severity of symptomology was defined as participants’ self-reported feelings 
(e.g., nervous, hopeless, restless, depressed, worthless) during the 30 days prior to study 
enrollment, as measured with the 6-item K6 scale (Kessler et al., 2010). A 5-point Likert scale is 
used to measure participants’ responses to each of the 6 items, from not at all (0) to all of the 
time (4). The K6 items are summed to compute that person’s level of psychological distress, 
ranging from 0 to 30. Higher scores indicate higher levels of distress. Lemieux et al. (2015) and 
Thomas (2017) reported Cronbach’s alphas of 0.88 and 0.91, respectively, indicating good 
internal consistency.  
Independent Variables 
Sociodemographic Characteristics. Sociodemographic characteristics, collected with 
the NOMs survey at baseline, included age, gender, race, employment status, disability status, 
living arrangement, and education level. Age was measured in years based on participants’ 
responses to the age-related NOMs item. Gender information was obtained from participants 
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with one self-report item and was dichotomized as male (0) and female (1). With regards to race, 
participants were asked to report whether they identified as Black, White, Hispanic, Asian, 
Pacific Islander, Alaska Native, or American Indian; however, given the response distribution 
reported by Lemieux et al. (2015), the current study dichotomized race as White (0) and Black 
(1). Employment status and disability status information was obtained from participants with one 
self-report NOMs item. Employment status included two categories, employed (1) and 
unemployed (0). Disability status was dichotomized as yes (1) and no (0), and coding was based 
on whether or not participants marked “disabled” as a reason for unemployment on the 
employment status self-report item. Regarding living arrangement, participants were asked to 
report type of residence (e.g., own house or apartment, with someone else, group home) 30 days 
prior to study enrollment. Responses of house or apartment ownership were coded as 1, and 
responses of living with someone else were coded as 0. Finally, education level was measured 
based on self-reported responses to the NOMs item inquiring about participants’ highest level of 
education completed. Response options included less than 12th grade, high school diploma or 
GED, vocational diploma, some college, and bachelor’s or graduate degree. Education level was 
dichotomized in the study as less than a high school education (0) and high school education or 
greater (1). 
Health Characteristics. Health characteristics for the study included the total number of 
prescribed medications, whether or not antipsychotic medications were prescribed at baseline, 
and self-assessed health. Information about prescribed medications included the frequency and 
type of all medications prescribed to participants that were recorded by nurse care managers at 
baseline. The number of prescribed medications was tallied using medication lists recorded on 
IHP-BPHIF forms by nurse care managers. Participants who were prescribed antipsychotic 
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medications at baseline were coded as 1 (yes), and participants who were not were coded as 0 
(no). Finally, self-assessed health was measured with the GSRH question incorporated in the 
NOMs survey. This item asked: “How would you rate your overall health right now?” GSRH 
response options ranged from 1 (poor) to 5 (excellent).  
Health-risk characteristics included participants’ self-reported use of alcohol, tobacco, 
and illicit or non-prescribed drugs at baseline, as well as self-reports indicating whether 
participants had ever been diagnosed with hypertension, diabetes, and heart disease. Three self-
report items on the IHP-BPHIF assessed participants’ current use of alcohol, tobacco, and illicit 
or non-prescribed drugs. Use of each of the three substances was coded as 0 (no) or 1 (yes). 
Finally, three self-report items on the IHP-BPHIF asked participants whether they had ever been 
diagnosed with hypertension, diabetes, and heart disease. Response options for these latter items 
were dichotomized (0=no, 1=yes). 
 Treatment-Related Characteristics. Treatment-related characteristics included access 
to reliable transportation, the number of clinic services received, whether participants had a 
primary health care provider at baseline, and clinic site. Access to reliable transportation was 
assessed with one IHP-BPHIF item asking participants to self-report whether they had access to 
reliable transportation. Responses for access to reliable transportation were dichotomized as no 
(0) and yes (1). Number of clinic services was defined as the total number of monthly health and 
mental health services (e.g., case management, treatment planning, primary care) received by 
participants, as recorded by nurse care managers at follow up on the NOMs 6-month 
reassessment survey. Primary health care provider at baseline refers to whether or not 
participants reported the name of a primary care physician at baseline, as recorded by nurse care 
managers on the IHP-BPHIF. Responses for primary health care provider at baseline were 
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dichotomized as yes (1) and no (0). Finally, clinic site refers to 1 of 3 CMH sites where 
participants were receiving integrated PBHC services. Center for Adult Behavioral Health 
(CABH), Margaret Dumas Mental Health (MDMH), and Gonzales Mental Health (GMH) were 
coded as 1, 2, and 3, respectively.  
Data Analysis 
A power analysis was conducted to confirm that a sample size of 311 was sufficient to 
detect a medium effect size (0.80), with a p value set at 0.05 (Rubin & Babbie, 1993). To 
summarize data, descriptive statistics for non-parametric variables (e.g., gender, race, 
employment status) are reported using frequencies and their percentages (Rubin & Babbie, 
2017). Descriptive statistics for parametric variables (e.g., number of health and mental health 
services, self-rated health) were computed, and the mean, standard deviation, and range are 
reported (Rubin & Babbie, 2017).  
 Paired samples t-tests were used to determine whether participants showed improvements 
from baseline to follow up on level of functioning, level of social support, and severity of 
symptomology (Rubin & Babbie, 2017). Bivariate analyses were used to examine associations 
between key variables of interest (i.e., sociodemographic, health, health-risk, treatment-related 
characteristics) and improvements in health and psychosocial functioning at 6 months out. Chi-
square tests of independence were computed to examine differences in the distribution of 
responses among categorical variables (e.g., disability status, health indicators, reliable 
transportation; Rubin & Babbie, 2017). Independent samples t-tests were computed to assess 
whether the mean scores on measures of continuous variables (e.g., age, number of medications) 
differed between those who did and did not show improvements in health and psychosocial 
functioning (Rubin & Babbie, 2017). 
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CHAPTER 5: RESULTS 
The current study examined associations between key variables of interest (i.e., 
sociodemographic, health, health-risk, and treatment characteristics) and health and psychosocial 
improvements in a sample of 311 CMH clients enrolled in integrated health programs.  
Sociodemographic Characteristics  
As seen in Table 1, the study sample included 157 men (51.1%) and 150 women (48.9%). 
The average age of participants was 45.7 (SD=13.1, Range=18-75). Nearly three fourths of the 
participants were Black (72.3%), and just over one fourth was White (27.7%). The majority was 
unemployed (87.7%), and just under one half (44.3%) was receiving disability benefits (see 
Table 1). A slightly greater proportion of participants reported living on their own (51.8%) than 
with someone else (48.2%). As seen in Table 1, well over half of participants reported having at 
least a 12th grade education (61.5%). 
Table 1. Sociodemographic Characteristics (N=272-307) 
                         M SD Range Frequency Valid % 





     
 Male - - - 157 51.1 
 Female - - - 150 48.9 
Race       
 Black - - - 211 72.3 
 White - - - 81 27.7 
Employment Status       
 Unemployed - - - 265 87.7 
 Employed - - - 37 12.3 
Disability Status       
 No Benefits - - - 170 55.7 
 Benefits - - - 135 44.3 
Living Arrangement        
 With Another  - - - 131 48.2 
 Own/Rented - - - 141 51.8 
(Table 1 continued)  
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  M SD Range Frequency Valid % 
Education       
 <12th Grade - - - 117 38.5 
 ≥ 12th Grade - - - 187 61.5 
 
Health Characteristics  
Table 2 displays information about the study sample’s health characteristics. On average, 
participants reported taking 4 prescription medications (SD=2.4, Range=0-12), and 87.1% 
reported being prescribed an antipsychotic medication. The mean score for participants on the 
measure of self-assessed health was 2.8 (SD=1.1, Range=1-5), indicating that, on average, 
participants viewed their health as between good and fair. 
Table 2. Health Characteristics (N=301-311) 
  M SD Range Frequency Valid % 
Number of Meds Baseline  4.0 2.4 0-12 - - 
 
Antipsychotic Meds Baseline 
      
Yes 
No 
- - - 271 87.1 
- - - 40 12.9 
Self-Assessed Health  2.8 1.1 1-5 - - 
 
Health-Risk Characteristics  
Table 3 shows information about relevant health-risk characteristics. Just over three 
fourths (76.6%) reported no alcohol use, and slightly over half (53.1%) reported tobacco use. A 
small proportion of the study sample (12.6%) reported using illicit or non-prescribed drugs. In 
terms of personal history of cardiometabolic disorders, over one half of participants reported a 
personal history of hypertension (54.2%), about one fifth reported a personal history of diabetes 
(20.2%), and just under one half (47.4%) reported a personal history of heart disease (see Table 
3).  
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Table 3. Health-Risk Characteristics (N=272-305) 
  M SD Range Frequency Valid % 
Personal Hx: Alcohol        
Yes 
No 
- - - 71 23.4 
- - - 232 76.7 
 
Personal Hx: Tobacco 
Yes 
No 
















- - - 143 46.9 




     
- - - 38 12.6 
- - - 263 87.4 
Personal Hx: HBP 
Yes 
No 
     
- - - 163 54.2 
- - - 138 45.8 
Personal Hx: Diabetes 
Yes 
No 
     
- - - 60 20.2 
- - - 237 79.8 
Personal Hx: Heart Disease 
Yes 
No 
     
- - - 129 47.4 
- - - 143 52.6 
      
Treatment-Related Characteristics  
As seen in Table 4, over three fourths of participants (78.3%) had access to reliable 
transportation. On average, enrollees received 1.6 clinical services each month (SD=0.9, 
Range=0-4.8), and just over half (55.1%) reported that they did not have a primary care 
physician at baseline. In terms of clinic site, Table 4 shows that 148 individuals were enrolled at 
MDMH (47.9%), 119 were enrolled at CABH (38.5%), and 42 were enrolled at GMH (13.6%). 
Table 4. Treatment-Related Characteristics (N=159-309) 
 M SD Range Frequency Valid % 
Reliable Transportation      
Yes 
No 
- - - 173 78.3 
- - - 48 21.7 
(Table 4 continued)  
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 M SD Range Frequency Valid % 
Number Clinic Services 1.6 0.9 0-4.8 - - 
PCP Baseline      
Yes 
No 
- - - 127 44.9 
- - - 156 55.1 
Clinic Site       
MDMH 
                       CABH 
                       GMH                                 
- - - 148 47.9 
- - - 119 38.5 
     - - - 42 13.6 
 
Retention  
 Among 311 participants, approximately half (N=152, 48.9%) was retained at 6 months.  
Improvement in Psychosocial Characteristics  
Paired samples t-tests were performed to determine whether participants showed 
improvements from baseline to follow up on measures of functioning (K6), social support (PSC), 
and symptomology (PF). As seen in Table 5, the mean follow-up K6 score (M=6.5) was 
significantly lower than the mean baseline K6 score (M=8.1), indicating decreased psychological 
distress. The mean PSC score increased from 15.4 (baseline) to 15.9 (follow up), and the mean 
PF score increased from 25.3 (baseline) to 27.8 (follow up). Improvements in level of social 
support and severity of symptomology were significant (see Table 5). 
Table 5. Differences from Baseline to Follow Up on Key Psychosocial Variables 
 Baseline Score Follow Up Score 95% CI for Mean Difference  
K6 M SD M SD Lower Upper T df 
 8.1 6.2 6.5 5.8 .75096 2.42364 3.756*** 125 
PSC M SD M SD Lower Upper T df 
 15.4 2.8 15.9 2.4 -.90890 -.14219 -2.711** 136 
PF M SD M SD Lower Upper T df 
 25.3 4.3 27.8 4.1 -3.20087 -1.93513 -8.031*** 124 
*p<.05, **p<.01, ***p<.001  
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Improvement in Health  
 As seen in Table 6, a smaller proportion of participants was at risk at follow up (40.7%) 
than at baseline (48.2%) with regard to systolic BP. However, slightly greater proportions 
showed at-risk diastolic BP and BMI scores at follow up (at 29.7% and 82.1%, respectively) than 
at baseline (at 28.8% and 80.7%, respectively).  
Table 6. Proportions of Participants at Risk at Baseline and Follow Up 
 Frequency Baseline Valid % Frequency Follow Up Valid %  
Systolic BP      
 At Risk 149 48.2 59 40.7  
 Not at Risk 160 51.8 86 59.3  
 
Diastolic BP 
     
 At Risk 89 28.8 43 29.7  
 Not at Risk 220 71.2 102 70.3  
BMI      
 At Risk 192 80.7 64 82.1  
 Not at Risk 46 19.3 14 17.9  
 
Factors Associated with Improvement in Psychosocial Characteristics 
Chi-square tests of independence were conducted to examine proportional differences in 
psychosocial functioning across key categorical sociodemographic, health, health-risk, and 
treatment characteristics (see Tables 7, 8, and 9). As seen in Table 8, unemployed individuals 
were significantly more likely to demonstrate improvement in functioning compared to those 
who were employed, at X2 = 12.035, df = 1, p<.001. Individuals who did not receive disability 
benefits were more likely than those receiving assistance to show improvement in functioning, at 
X2 = 4.861, df = 1, p<.05 (see Table 8). Compared to those who lived with someone else, those 
who owned or rented a home were more likely to exhibit improvement in functioning, at X2 = 
4.926, df = 1, p<.05 (see Table 8). With regard to social connectedness, those who did not 
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receive disability benefits were more likely than those receiving assistance to perceive higher 
levels of social connectedness, at X2 = 4.145, df = 1, p<.05 (see Table 9). Finally, those with 
access to reliable transportation were significantly more likely to perceive higher levels of social 
connectedness than those without reliable transportation, at X2 = 11.072, df = 1, p<.001 (see 
Table 9).  
Table 7. Proportional Differences: Improvement in Symptomology (K6)   
       No Improvement      Improvement p   N Valid % N Valid% 
Gender       
 Male 24 50.0 40 52.6  
 Female 24 50.0 36 47.4 .775 
Race       
 Black 30 65.2 56 76.7  
 White 16 34.8 17 23.2 .173 
Employment Status       
 Unemployed 42 89.4 63 84.0  
 Employed 5 10.6 12 16.0 .405 
Disability Status       
 No Benefits 25 52.1 39 52.0  
 Benefits 23 47.9 36 48.0 .993 
Living Arrangement       
 With Another 15 34.9 31 43.7  
 Own/Rented 28 65.1 40 56.3 .354 
Education       
 <12th Grade 18 37.5 24 32.0  
 ≥12th Grade 30 62.5 51 68.0 .530 
Antipsychotic Meds Baseline       
 Yes 44 88.0 67 88.2  
 No 6 12.0 9 11.8 .979 
Personal Hx: Alcohol       
 Yes 11 22.4 16 21.3  
 No 38 77.6 59 78.7 .883 
Personal Hx: Tobacco        
 Yes 30 61.2 41 54.7  
 No 19 38.8 34 45.3 .471 
Personal Hx: Drugs       
 Yes 3 6.1 11 14.7  
 No  46 93.9 64 85.3 .142 




  No Improvement Improvement  
  N Valid % N Valid % p 
Personal Hx: HBP       
  26 52.0 49 65.3  
  24 48.0 26 34.7 .136 
Personal Hx: Diabetes       
 Yes 13 26.5 16 21.3  
 No 36 73.5 59 78.7 .504 
Personal Hx: Heart Disease        
 Yes 4 9.1 9 12.7  
 No 40 90.9 62 87.3 .555 
Reliable Transportation       
 Yes  33 84.6 45 75.0  
 No 6 15.4 15 25.0 .253 
PCP Baseline       
 Yes 24 54.5 31 43.7  
 No 20 45.5 40 56.3 .256 
Clinic Site             
 MDMH       22             44.9              41            54.7  
 CABH       23                  46.9                 26      35.7  
 GMH        4       8.2       8        10.7       .391 
 
Table 8. Proportional Differences: Improvement in Functioning (PF)   
      No Improvement      Improvement p   N Valid % N Valid % 
Gender       
 Male 18 48.6 42 48.8  
 Female 19 51.4 44 51.2 .985 
Race       
 Black 22 66.7 62 74.7  
 White 11 33.3 21 25.3 .383 
Employment Status       
 Unemployed 24 66.7 78 91.8  
 Employed 12 33.3 7 8.2 .001 
Disability Status       
 No Benefits 25 67.6 39 45.9  
 Benefits 12 32.4 46 54.1 .027 
Living Arrangement       
 With Another 20 54.1 26 32.5  
 Own/Rented 17 45.9 54 67.5 .026 
Education       
 <12th Grade 11 29.7 31 36.5  
 ≥12th Grade 26 70.3 54 63.5 .471 
(Table 8 continued)      
	
	 56	
  No Improvement Improvement  
  N Valid % N Valid % p 
Antipsychotic Meds Baseline       
            Yes  34 89.5 78 89.7  
            No  4 10.5 9 10.3 .976 
Personal Hx: Alcohol       
 Yes 9 23.7 16 18.8  
 No 29 76.3 69 81.2 .536 
Personal Hx: Tobacco        
 Yes 22 57.9 42 49.4  
 No 16 42.1 43 50.6 .384 
Personal Hx: Drugs       
 Yes 4 10.5 11 12.9  
 No 34 89.5 74 87.1 .705 
Personal Hx: HBP       
 Yes 18 50.0 58 66.7  
 No 18 50.0 29 33.3 .083 
Personal Hx: Diabetes       
 Yes 6 17.6 24 27.6  
 No 28 82.4 63 72.4 .255 
Personal Hx: Heart Disease        
 Yes 3 8.8 9 11.1  
 No 31 91.2 72 88.9 .714 
Reliable Transportation       
 Yes  20 76.9 58 80.6  
 No 6 23.1 14 19.4 .694 
PCP Baseline       
 Yes 14 45.2 39 47.6  
 No 17 54.8 43 52.4 .820 
Clinic Site       
 MDMH       15     40.5      51            59.3  
 CABH       17               49.5      27            31.4  
 GMH        5     13.5       8     9.3               .160 
 
Table 9. Proportional Differences: Improvement in Social Connectedness (PSC)   
      No Improvement      Improvement p   N Valid % N Valid % 
Gender       
 Male 41 48.2 26 51.0  
 Female 44 51.8 25 49.0 .757 
Race       
 Black 56 71.8 37 74.0  
 White 22 28.2 13 26.0 .785 
(Table 9 continued) 
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  No Improvement Improvement  
  N Valid % N Valid % p 
Employment Status       
 Unemployed  74 88.1 41 82.0  
 Employed  10 11.9 9 18.0 .328 
Disability Status       
 No Benefits 39 45.9 32 64.0  
 Benefits 46 54.1 18 36.0 .042 
Living Arrangement       
 With Another 33 40.7 19 42.2  
 Own/Rented 48 59.3 26 57.8 .871 
Education       
 <12th Grade 30 35.3 16 32.0  
 ≥12th Grade 55 64.7 34 68.0 .697 
Antipsychotic Meds Baseline       
 Yes 79 91.9 43 84.3  
 No 7 8.1 8 15.7 .171 
Personal Hx: Alcohol       
 Yes 19 22.4 9 18.0  
 No 66 77.6 41 82.0 .547 
Personal Hx: Tobacco        
 Yes 41 48.2 32 64.0  
 No 44 51.8 18 36.0 .076 
Personal Hx: Drugs       
 Yes 8 9.4 8 16.0  
 No 77 90.6 42 84.0 .253 
Personal Hx: HBP       
 Yes 53 63.1 28 56.0  
 No 31 36.9 22 44.0 .417 
Personal Hx: Diabetes       
 Yes 18 21.4 13 26.5  
 No 66 78.6 36 73.5 .502 
Personal Hx: Heart Disease        
 Yes 10 12.5 5 10.9  
 No 70 87.5 41 89.1 .786 
Reliable Transportation       
 Yes  62 89.9 24 63.2  
 No 7 10.1 14 36.8 .001 
PCP Baseline       
 Yes 40 51.3 19 40.4  
 No 38 48.7 28 59.6 .239 
Clinic Site       
 MDMH 48 56.5 23 46.0  
 CABH 30 35.3 21 42.0  
 GMH 7 8.2 6 12.0 .474 
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Independent samples t-tests were computed to assess whether the mean scores on 
measures of continuous sociodemographic, health, and health-risk variables differed between 
those who did and did not show improvement in psychosocial functioning (see Tables 10, 11, 
and 12). No significant differences emerged between participants who did and did not 
demonstrate improvement in psychosocial functioning across any of the latter characteristics.  
Table 10. Mean Differences: Improvement in Symptomology (K6) 
 M SD t df p 
Age      
 No Improvement 45.6 12.1    
 Yes Improvement 47.5 12.4 -.842 120 .401 
Number of Meds Baseline      
 No Improvement 4.2 3.1    
 Yes Improvement 4.4 2.5 -.413 121 .681 
Self-Assessed Health      
 No Improvement 2.9 1.1    
 Yes Improvement 2.6 1.1 1.072 120 .286 
Number Clinic Services      
 No Improvement 1.7 0.8    
 Yes Improvement 1.7 0.9 -.065 118      .948 
  
Table 11. Mean Differences: Improvement in Functioning (PF) 
 M SD t df p 
Age      
 No Improvement 44.1 10.4    
 Yes Improvement 48.5 12.7 -1.842 119 .068 
Number of Meds Baseline      
 No Improvement 4.4 3.1    
 Yes Improvement 4.5 2.7 -.141 122 .888 
Self-Assessed Health      
 No Improvement 2.9 1.2    
 Yes Improvement 2.6 1.1 1.216 119 .227 
Number Clinic Services      
 No Improvement 1.5 0.7    





Table 12. Mean Differences: Improvement in Social Connectedness (PSC) 
 M SD t df p 
Age      
 No Improvement 47.8 11.5    
 Yes Improvement 45.8 12.7 .909 132 .365 
Number of Meds Baseline      
 No Improvement 4.6 2.7    
 Yes Improvement 4.2 2.9 .740 132 .461 
Self-Assessed Health      
 No Improvement 2.7 1.1    
 Yes Improvement 2.8 1.3 -.531 130 .596 
Number Clinic Services      
 No Improvement 1.6 1.0    
 Yes Improvement 1.7 0.9 -.433 129 .666 
 
Characteristics Associated with Improvement in Health 
Chi-square tests of independence were conducted to examine proportional differences in 
health across key categorical sociodemographic, health, health-risk, and treatment characteristics 
(see Tables 13, 14, and 15). As seen in Table 13, individuals who lived with someone else were 
significantly less likely to be at risk on systolic BP than those who owned or rented a home, at X2 
= 7.371, df = 1, p<.01. Participants who received services at MDMH were more likely to have 
diastolic BP scores in the normal range (59.0%) compared to participants who received care at 
CABH (29.0%) and GMH (12.0%), at X2 = 14.036, df  = 1, p<.001 (see Table 14). Those who 
received disability benefits were significantly less likely to have at-risk BMI scores than those 
who were not receiving assistance, at X2 = 4.447, df  = 1, p<.05 (see Table 15). Although not 
statistically significant, the proportion of Black participants who were not at risk with regard to 
systolic BP (85.3%) was considerably greater than White participants (14.7%; see Table 13). 
Further, a greater proportion of individuals without diabetes (81.0%) were not at risk with regard 
to systolic BP compared to individuals with diabetes (19.0%).  
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Table 13. Proportional Differences: Improvement in Systolic BP   
      No Improvement      Improvement p   N Valid % N Valid % 
Gender       
 Male 16 43.2 19 54.3  
 Female 21 56.8 16 45.7 .349 
Race       
 Black 22 66.7 29 85.3  
 White 11 33.3 5 14.7 .074 
Employment Status       
 Unemployed 31 83.8 29 85.3  
 Employed 6 16.2 5 14.7 .861 
Disability Status       
 No Benefits 18 48.6 19 55.9  
 Benefits 19 51.4 15 44.1 .542 
Living Arrangement       
 With Another 8 21.6 17 53.1  
 Own/Rented 29 78.4 15 46.9 .007 
Education       
 <12th Grade 13 35.1 7 21.2  
 ≥12th Grade 24 64.9 26 78.8 .198 
Antipsychotic Meds Baseline       
 Yes 36 94.7 31 88.6  
 No 2 5.3 4 11.4 .338 
Personal Hx: Alcohol       
 Yes 9 23.7 10 28.6  
 No 29 76.3 25 71.4 .634 
Personal Hx: Tobacco        
 Yes 18 47.4 15 42.9  
 No 20 52.6 20 57.1 .699 
Personal Hx: Drugs       
 Yes 6 15.8 6 17.1  
 No 32 84.2 29 82.9 .876 
Personal Hx: HBP       
 Yes 29 78.4 26 74.3  
 No 8 21.6 9 25.7 .683 
Personal Hx: Diabetes       
 Yes 19 33.3 16 19.0  
 No 38 66.7 68 81.0 .054 
Personal Hx: Heart Disease        
 Yes 5 15.2 6 17.6  
 No 28 84.8 28 82.4 .783 





  No Improvement Improvement  
  N Valid % N Valid % p 
Reliable Transportation       
 Yes  22 73.3 21 77.8  
 No  8 26.7 6 22.2 .697 
PCP Baseline       
 Yes 19 54.3 15 45.5  
 No 16 45.7 18 54.5 .467 
Clinic Site       
 MDMH       27     46.6      43    50.6  
 CABH       20     34.5      34    40.0  
 GMH       11     19.0               8        9.4      .251 
  
 
Table 14. Proportional Differences: Improvement in Diastolic BP   
       No Improvement      Improvement p   N Valid % N Valid % 
Gender       
 Male 9 39.1 8 50.0  
 Female 14 60.9 8 50.0 .501 
Race       
 Black 17 73.9 10 76.9  
 White 6 26.1 3 32.1 .841 
Employment Status       
 Unemployed 19 82.6 14 93.3  
 Employed 4 17.4 1 6.7 .339 
Disability Status       
 No Benefits 13 56.5 7 46.7  
 Benefits 10 43.5 8 53.3 .552 
Living Arrangement       
 With Another 11 50.0 4 28.6  
 Own/Rented 11 50.0 10 71.4 .204 
Education       
 <12th Grade 9 40.9 5 33.3  
 ≥12th Grade 13 59.1 10 66.7 .641 
Antipsychotic Meds Baseline       
 Yes 19 82.6 15 88.2  
 No 4 17.4 2 11.8 .622 
Personal Hx: Alcohol       
 Yes 8 34.8 6 35.3  
 No 15 65.2 11 64.7 .973 
Personal Hx: Tobacco        
 Yes 12 52.2 10 58.8  
 No 11 47.8 7 41.2 .676 
(Table 14 continued) 
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  No Improvement Improvement  
  N Valid % N Valid % p 
Personal Hx: Drugs       
 Yes  7 30.4 4 23.5  
 No  16 69.6 13 76.5 .629 
Personal Hx: HBP       
 Yes 18 81.8 16 94.1  
 No 4 18.2 1 5.9 .255 
Personal Hx: Diabetes       
 Yes 8 34.8 6 37.5  
 No 15 65.2 10 62.5 .862 
Personal Hx: Heart Disease        
 Yes 4 17.4 3 20.0  
 No 19 82.6 12 80.0 .839 
Reliable Transportation       
 Yes  13 68.4 12 75.0  
 No 6 31.6 4 25.0 .668 
PCP Baseline       
 Yes 11 57.9 9 69.2  
 No 8 42.1 4 30.8 .515 
Clinic Site       
 MDMH       11     25.6       59    59.0  
 CABH       25     58.1       29    29.0  
 GMH        7     16.3       12    12.0      .001 
 
Table 15. Proportional Differences: Improvement in BMI   
      No Improvement      Improvement p   N Valid % N Valid % 
Gender       
 Male 49 44.1 3 75.0  
 Female 62 55.9 1 25.0 .223 
Race       
 Black 78 73.6 2 50.0  
 White 28 26.4 2 50.0 .298 
Employment Status       
 Unemployed 90 82.6 4 100.0  
 Employed 19 17.4 0 0.0 .360 
Disability Status       
 No Benefits 59 53.6 0 0.0  
 Benefits 51 46.4 4 100.0 .035 
Living Arrangement       
 With Another 40 38.1 1 33.3  
 Own/Rented 65 61.9 2 66.7 .867 
(Table 15 continued) 
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  No Improvement Improvement  
  N Valid % N Valid % p 
Education       
 <12th Grade  38 35.2 1 25.0  
 ≥12th Grade  70 64.8 3 75.0 .675 
Antipsychotic Meds Baseline       
 Yes 101 89.4 4 100.0  
 No 12 10.6 0 0.0 .491 
Personal Hx: Alcohol       
 Yes 27 24.1 1 25.0  
 No 85 75.9 3 75.0 .967 
Personal Hx: Tobacco        
 Yes 57 50.9 1 25.0  
 No 55 49.1 3 75.0 .309 
Personal Hx: Drugs       
 Yes 13 11.6 1 25.0  
 No 99 88.4 3 75.0 .419 
Personal Hx: HBP       
 Yes 71 64.0 3 75.0  
 No 40 36.0 1 25.0 .651 
Personal Hx: Diabetes       
 Yes 32 29.1 0 0.0  
 No 78 70.9 4 100.0 .203 
Personal Hx: Heart Disease        
 Yes 11 10.7 1 25.0  
 No 92 89.3 3 75.0 .373 
Reliable Transportation       
 Yes  69 83.1 4 100.0  
 No 14 16.9 0 0.0 .370 
PCP Baseline       
 Yes 56 56.0 2 66.7  
 No 44 44.0 1 33.3 .714 
Clinic Site       
 MDMH       20     31.3       6    42.9  
 CABH       30     46.9       5    35.7  
 GMH       14     21.9       3    21.4      .676 
 
Independent samples t-tests were computed to assess whether the mean scores on 
measures of continuous sociodemographic, health, and health-risk variables differed between 
those who did and did not show improvement in health (see Tables 16, 17, and 18). No 
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significant differences emerged between participants who did and did not demonstrate 
improvement in health across any of the latter characteristics. 
Table 16. Mean Differences: Improvement in Systolic BP 
 M SD t df p 
Age      
 At Risk 48.3 11.3    
 Not at Risk 50.1 9.5 -.732 70 .467 
Number of Meds Baseline      
 At Risk 4.5 2.9    
 Not at Risk 4.4 2.7 -.129 70 .898 
Self-Assessed Health      
 At Risk 2.6 1.1    
 Not at Risk 2.9 1.1 1.196 70 .236 
Number Clinic Services      
 At Risk 1.5 0.9    
 Not at Risk 1.7 0.9 1.649 137 .101 
 
Table 17. Mean Differences: Improvement in Diastolic BP 
 M SD t df p 
Age      
 At Risk 44.8 11.7    
 Not at Risk 49.3 10.1 1.255 37 .217 
Number of Meds Baseline      
 At Risk 3.3 1.8    
 Not at Risk 4.3 2.1 1.575 37 .124 
Self-Assessed Health      
 At Risk 2.5 1.1    
 Not at Risk 2.4 1.2 -.129 35 .898 
Number Clinic Services      
 At Risk 1.5 0.8    
 Not at Risk 1.7 1.0 1.363 147 .175 
 
Table 18. Mean Differences: Improvement in BMI 
 M SD t df p 
Age      
 At Risk 46.8 12.2    
 Not at Risk 54.8 4.5 1.294 112 .198 
Number of Meds Baseline      
 At Risk 4.6 2.8    
 Not at Risk 5.0 3.6 .307 114 .759 
(Table 18 continued) 
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 M SD t df p 
Self-Assessed Health      
 At Risk 2.8 1.1    
 Not at Risk 3.3 1.3 .873 112 .384 
Number Clinic Services      
 At Risk 1.7 1.1    






















CHAPTER 6: DISCUSSION  
 The current study examined correlates (i.e., sociodemographic, health, health-risk, and 
treatment-related characteristics) of health and psychosocial improvements among individuals 
with thought disorders receiving integrated PBHC services in 3 CMH settings. Prior to this 
analysis, no longitudinal study to date had examined correlates of improvement on critical health 
and psychosocial outcomes among CMH clients diagnosed with thought disorders in integrated 
PBHC programs.  
Sociodemographic, Health, Health-Risk, and Treatment-Related Characteristics 
 As with the community-based PCARE trial (Druss et al., 2010), African-American 
participants were overrepresented in the current study (72.3%). This latter finding is consistent 
with extant research demonstrating that African Americans are disproportionately diagnosed 
with schizophrenia (Barnes, 2008, 2013). Participants in the present study represented a 
relatively disadvantaged group of individuals with thought disorders. Although over half had a 
high school education or greater (61.5%), the vast majority (87.7%) was unemployed. In 
addition, a slightly greater portion of IHP enrollees (44.3%) was receiving disability benefits 
than PCARE enrollees (39.3%).  
The prevalence of comorbid health conditions among participants in the current study is 
similar to that reported in the few existing studies that have sampled CMH clients. For example, 
about half of participants with thought disorders in both the current study and the national 
cardiometabolic screening program study (Correll et al., 2010) had hypertension (at 54.2% and 
51.0%, respectively). These rates of high BP are slightly greater than those reported by Druss et 
al. (2010) in the PCARE study (at 45.5%). Rates of self-reported diabetes were also slightly 
higher in the current study (20.2%) than in the PCARE study (Druss et al., 2010; 17.9%). Nearly 
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half of participants in the current study (47.4%) reported comorbid cardiovascular disease, 
consistent with research showing disproportionate prevalence of cardiac disease among clients in 
CMH agencies (Parks et al., 2006).  
 The prevalence of co-occurring tobacco, alcohol, and other substance use was much 
lower than that reported by Hartz et al. (2014). Just over half of the current study sample were 
daily smokers; this prevalence is markedly less than the rates of smoking reported in Hartz et 
al.’s (2014) large-scale epidemiological study of patients with thought disorders (at 73.4%). 
Rates of self-reported alcohol use (23.4%) were also considerably lower than those described by 
Hartz et al. (2014; 28.3%). Use of illicit substances was reported by 12.6% of participants in the 
current study, also a lower rate than that reported by Hartz et al. (2014; 39.4%). The differences 
in reported rates of health-risk behaviors may be explained by underreporting in the current 
study. First, objective measures (e.g., urinalysis testing) were not utilized to confirm self-
reported use of substances, which was recommended by Thomas (2017). In addition, participants 
may have been reluctant to disclose actual amounts because of social desirability bias (Rubin & 
Babbie, 2017).  
Factors Associated with Improvement in Psychosocial Characteristics 
 One major objective of the current study was to examine correlates of certain 
psychosocial characteristics among individuals with thought disorders. Participants in the current 
descriptive study showed improvement in level of functioning and level of social support at 6 
months out. With regard to sociodemographic characteristics, employment status, disability 
status, and living arrangements were significantly associated with improvement in level of 
functioning at 6 months out. Individuals who were unemployed at baseline were more likely to 
demonstrate improvement in level of functioning at follow up than those who were employed. 
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This latter finding seems counterintuitive because existing research has shown positive 
correlations between employment and social functioning, symptom severity, and quality of life 
among individuals with thought disorders (e.g., Marwaha & Johnson, 2004). It is possible that 
individuals who were employed full time or part time upon study enrollment may have exhibited 
better functioning prior to enrolling in the program. Conversely, unemployed individuals, 
potentially lower functioning at baseline, may have experienced greater gains upon receiving 
integrated PBHC services. It is also possible that employed participants were not able to avail 
themselves of a sufficient amount of services because of scheduling constraints. Thus, additional 
research is needed to understand the relationship between participants’ employment status and its 
relationship to service utilization and client outcomes, including level of functioning.  
Individuals who did not receive disability benefits demonstrated greater improvement in 
level of functioning at 6 months out. It is likely that participants who were not receiving benefits 
upon IHP enrollment were much higher functioning than those who qualified for benefits 
because of more severe symptomology. Compared to those who lived with someone else, 
individuals who owned or rented a home were more likely to exhibit improvement in level of 
functioning at follow up. Existing studies have yielded conflicting results with regard to living 
arrangement. Salokangas (1997) conducted a longitudinal study of 227 first-contact 
schizophrenia patients and found that those living with family members exhibited better 
functional outcomes than those not living with their families. However, Hansson et al. (2002) 
found that people with schizophrenia who lived independently (N=251) had a better quality of 
life and higher levels of perceived independence than those living with family members (N=78). 
It is possible that participants in the current study who owned or rented their own home had the 
ability to live independently, which suggests that they were higher functioning at baseline. Those 
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who lived with others may have either needed assistance or were caring for others who needed 
assistance, which compromised their day-to-day functioning. However, information about 
activities of daily living and caregiving responsibilities was not collected in the present study. 
The association between a particular living arrangement and level of functioning is decidedly 
complex and warrants further exploration in future studies. Finally, individuals who did not 
receive disability benefits were more likely to perceive higher levels of social connectedness 
than those who did. A reason for this finding could be that participants who were not receiving 
benefits may have relied on family and kinship networks for material (e.g., transportation) and 
emotional support (McFarlane, Dixon, Lukens, & Lucksted, 2003), which subsequently 
influenced their perception of social connectedness. From this perspective, those who were not 
receiving benefits may have had more robust social support systems out of necessity. 
Conversely, participants who were receiving disability benefits may have relied on more formal 
sources of support. The current study did not measure specific activities of daily living. Thus, 
additional conceptualization of key variables is needed to shed light on the complex 
interrelationships among sociodemographic and psychosocial characteristics of persons with 
thought disorders receiving integrated PBHC services.  
Individuals with access to reliable transportation were significantly more likely to 
perceive higher levels of social connectedness. Palmer et al. (2002) conducted a study with 83 
middle-aged and older-adult outpatients with schizophrenia and found that those who drove 
(43.4%) exhibited better functional capacity. It is possible that participants with reliable 
transportation had easier access to organizations and agencies that offer informal sources of 
recovery and other supports (e.g., IHP wellness programs, self-help groups, adult day care 
programs, church groups), thereby increasing their perception of social connectedness. On the 
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other hand, it is also possible that participants with less social support had fewer individuals in 
their social networks to assist them with transportation.  
No health or health-risk characteristics were associated with improvements on any 
psychosocial characteristics. In other words, medications, health-risk behaviors, and health 
conditions did not distinguish those who improved from those who did not on measures on 
functioning, social connectedness, and psychological distress. These findings are inconsistent 
with those published by Lemieux et al. (2015), who reported significant interrelationships among 
key health and psychosocial variables. It is possible that attrition, program length, and sample 
differences contributed to disparate findings.    
Characteristics Associated with Improvement in Health 
 The second major objective of the current study was to examine correlates of 
improvement in health among individuals with thought disorders. A notable proportion of IHP 
participants experienced improvement in systolic BP (with at-risk rates decreasing from 48.2% 
to 40.7%), consistent with Putz et al. (2015). However, unlike participants in the latter study who 
demonstrated marked improvement in diastolic BP, a slightly greater proportion of IHP 
participants showed at-risk diastolic BP scores at follow up (29.7%) than at baseline (28.8%). 
Also inconsistent with findings by Putz et al. (2015), who reported significant decreases in 
participants’ BMI scores, a slightly greater proportion of IHP participants had at-risk BMI scores 
at follow up (82.1%) than at baseline (80.7%). Increases in diastolic BP and BMI scores in the 
current sample may be explained by the influence of antipsychotic medications and associated 
metabolic side effects (Tandon et al., 2008). Future studies should examine type of psychotropic 
medication when examining correlates of improvement in this population.  
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With regard to sociodemographic factors, characteristics of living arrangements and 
disability status were significantly associated with improvement in certain health characteristics 
at 6 months out. A significantly greater proportion of individuals who lived with someone else 
experienced improvement in systolic BP, as compared to those who lived on their own. It is 
possible that those who lived with someone else received medication reminders from family 
members, subsequently resulting in improved systolic BP. Without additional information about 
the nuances of participants’ living situations, it is difficult to interpret this latter association with 
confidence. As compared to those who did not receive disability benefits, those who did receive 
assistance were significantly more likely to experience improvement in BMI from baseline to 
follow up. It is possible that those with benefits were afforded greater continuity of IHP 
programs, resulting in a reduction in BMI; however, such speculation would need to be 
confirmed with additional data about service utilization.  
Although not statistically significant, the proportion of Black participants who showed 
improvement on systolic BP was substantially greater than that of White participants. It is 
plausible that a greater proportion of Blacks than Whites were at risk on systolic BP at baseline, 
and the improvement could reflect adherence to prescribed BP medications. The design of the 
current study does not allow definitive conclusions to be drawn. Not significantly but in a 
clinically meaningful fashion, a notably greater proportion of individuals who reported that they 
did not have diabetes at baseline showed improvement from baseline to follow up on systolic BP, 
as compared to those who did report having diabetes at baseline. It is likely that participants 
without diabetes at baseline had fewer complications and cardiometabolic conditions (Parks et 
al., 2006). Conversely, those with diabetes may have faced additional risks. For example, Gough 
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(2005) showed that individuals with comorbid thought disorders and diabetes faced a variety of 
health challenges, hampering progress in treatment.  
With regard to treatment-related characteristics, clinic site was significantly associated 
with improvement in health at follow up. Individuals who received IHP services at MDMH were 
more likely to experience improvement in diastolic BP than participants who received services at 
CABH and GMH. Anecdotal reports from MDMH staff suggest that the client population was 
more stable and experienced greater continuity of treatment (C. Lemieux, personal 
communication, November 27, 2017). Although not assessed in the current study, it is plausible 
that clinic characteristics influence treatment continuity and subsequent improvements in health. 
The current study did not examine site differences. Thus, additional research is needed to 
examine the influence of provider and clinic characteristics on participants’ health outcomes.  
None of the health and health-risk characteristics were associated with improvement in 
objective indicators of health. This means that number of prescribed medications, whether or not 
antipsychotic medications were prescribed at baseline, self-assessed health, and self-reported 
history of substance use and cardiometabolic conditions did not distinguish those who 
experienced improvements on objective measures of health from those who did not. These 
findings are also inconsistent with those reported by Lemieux et al. (2015), who reported 
significant interrelationships among key health-related factors and health outcomes. As 
mentioned previously, differences may be explained by attrition, program length, and sample 
differences.   
Conclusions 
 Key findings in the current study highlight the relevance of certain sociodemographic 
(i.e., employment status, disability status, living arrangement) and treatment-related (i.e., reliable 
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transportation, clinic site) characteristics to health and psychosocial improvements in a sample of 
CMH clients enrolled in co-located PBHC programs. No health or health-risk characteristics 
were significantly associated with improvement at 6 months out. Additional concluding 
observations can be made regarding study limitations, study strengths, future research, and 
implications for the social work field.  
Limitations and Strengths 
 As with all longitudinal studies, it is important to consider the methodological limitations 
that may have impacted study results. Firstly, the current study is correlational in design, so 
causality cannot be inferred. Data were collected from 3 CMH settings in one geographical area, 
limiting generalizability of the findings to other co-located PBHC programs. The sample size 
(N=311) is also a weakness, as smaller samples increase the likelihood of Type II errors 
(Hackshaw, 2008). Further, attrition resulted in a notable amount of missing data on several 
study variables, decreasing the number of paired cases in correlational analyses (Rubin & 
Babbie, 2017). Larger confirmatory studies should be conducted in attempts to replicate the 
findings of the present study. Future studies should employ random stratification sampling, and 
data should be collected from multiple sites to increase representativeness. Future analyses 
should also include additional longitudinal data, as 6 months may have been insufficient for 
participants to show improvements. Measurement may be a problematic issue, as self-report 
items introduce potential problems with reliability and validity. For example, individuals may 
have underreported certain self-report items (e.g., use of illicit substances) because of social 
desirability bias (Rubin & Babbie, 2017). Also related to measurement, there may have been data 
entry errors, subsequently resulting in inaccuracies. Finally, the current study utilized secondary 
data, limiting the number of potential research questions and study variables. There may be 
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relevant correlates of psychosocial and health improvements that were not measured in the 
original study. For example, studies have found that religiosity and spirituality are associated 
with a number of variables that are relevant to health, such as level of psychopathology, social 
integration, suicide risk, and substance use (Grover, Davuluri, & Chakrabarti, 2014). Religiosity 
has also been associated with treatment compliance (Grover et al., 2014). Given the 
overrepresentation of African Americans in the current study, along with a substantial corpus of 
research underscoring the importance of religious belief and spirituality among African 
Americans (Sanchez, Chapa, Ybarra, & Martinez, 2012), future research should incorporate 
measures of these latter concepts when examining health and wellbeing. 
 Despite its limitations, the current study contributes to the growing knowledge base on 
integrated PBHC programs and the clients who receive these services. It is the first known 
longitudinal study to examine correlates of improvements in health and psychosocial 
characteristics among individuals with thought disorders receiving integrated PBHC services in 
CMH settings. The few published studies that sampled CMH clients receiving co-located 
services focused exclusively on program outcomes (Druss et al., 2010; Putz et al., 2015) and 
descriptive information (Lemieux et al., 2015), not the variables that may predict improvement. 
Results from the current study showed that non health-related factors emerged as significant 
correlates of improvement among individuals with thought disorders, suggesting that social 
determinants are relevant for this population. No health or health-risk characteristics were 
significantly associated with improvement. These findings are counterintuitive, as existing 
studies (Lemieux et al., 2015) suggest the importance of both psychosocial and health-related 
characteristics when considering whole-person health.  
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Implications for Social Work Research 
 Research focused on recipients of co-located PBHC services is scant and remains a 
worthy pursuit. The current study examined associations among sociodemographic and 
treatment-related characteristics and improvements in health and psychosocial characteristics. 
Future studies should attempt to replicate these findings with larger samples (Hackshaw, 2008), 
and data should be collected from multiple sites in different geographical areas. Further, future 
analyses should implement stratified sampling methods to increase representativeness. 
Researchers should design studies that collect objective data (Thomas, 2017) in order to confirm 
participant self-reports, and these analyses should gather additional longitudinal data in order to 
allow more time for improvement. Future research should include potentially influential 
variables that may predict improvement, such as religion and spirituality (Grover et al., 2014), 
caregiving responsibilities, and peer support (Lemieux et al., 2015). Finally, future studies 
should attempt to collect follow-up data from all participants, even those who do not return for 
services, in order to better understand differences between those who do and do not show 
improvement.  
Implications for Social Work Practice   
	 The current study highlights the relevance of social determinants of health among 
individuals with thought disorders. Social workers should ask clients questions about their 
material (e.g., transportation and disability benefits) and emotional (e.g., family and peers) 
resources as part of a comprehensive assessment. Practitioners should also conduct regular 
follow-up assessments to capture changes in these resources. The present study also highlights 
the longstanding health disparities faced by individuals with thought disorders and the 
cumulative effects of inadequate access to health care. In attempts to eliminate these disparities, 
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social workers should use plain language when discussing health concerns with clients and also 
help to coordinate care when clients need specialty services (Druss et al., 2010). Further, social 
workers should adopt educational roles in CMH settings, teaching other providers about CMH 
clients’ unique needs. Finally, many participants in the current study did not return for services at 
follow up, so social workers should work towards improving treatment adherence and 
appointment attendance, both of which are significantly associated with health and psychosocial 
improvements (Adair et al., 2005; Druss & Walker, 2011). This might involve helping clients 
secure access to reliable transportation when needed.  
Implications for Social Work Education  
 Training and education are necessary to enhance competencies among social workers 
who serve CMH clients receiving integrated PBHC services. Schools of social work should 
expand existing curricula to prepare graduates for practice in integrated health settings. For 
example, faculty may introduce core competencies for behavioral health and primary care (see, 
e.g., Hoge, Morris, Laraia, Pomerantz, & Farley, 2014) in practice and diagnostic courses. 
Diversity classes should highlight the overlapping and interdependent systems of discrimination 
and disadvantage experienced by CMH clients in order to increase cultural competency and 
understanding of the unique needs of individuals with SMI. Additionally, social work students 
should have the opportunity to apply new knowledge in the field, subsequently improving their 
ability to function professionally in integrated settings. Finally, it is critical that social workers 
engage in continuing education in order to learn the latest knowledge about clients with SMI and 
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